-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WHadHDtgRACL6787K+7aZhwR2XkevkUzpONZBrqIeNjQqQjzgcqf35tPYuFjWIlH ah7LpeNp/FMT9fTuKFnYwA== 0000890566-00-000549.txt : 20000417 0000890566-00-000549.hdr.sgml : 20000417 ACCESSION NUMBER: 0000890566-00-000549 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 19991231 FILED AS OF DATE: 20000414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 943123681 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: SEC FILE NUMBER: 000-23413 FILM NUMBER: 601621 BUSINESS ADDRESS: STREET 1: 100 NE LOOP 410 STREET 2: STE 820 CITY: SAN ANTONIO STATE: TX ZIP: 78216-4749 BUSINESS PHONE: 2103496400 MAIL ADDRESS: STREET 1: 100 NE LOOP 410 STREET 2: STE 820 CITY: SAN ANTONIO STATE: TX ZIP: 78216 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 10-K 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X ] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 1999 Commission File Number: 000-23413 INTERLEUKIN GENETICS, INC. (Name of Small Business Issuer in its Charter) TEXAS 94-3123681 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 100 N.E. LOOP 410, SUITE 820 SAN ANTONIO, TEXAS 78216 (Address of principal executive offices)(Zip Code) Issuer's Telephone Number: (210) 349-6400 Securities registered under Section 12(b) of the Exchange Act: (Title of each class) (Name of each exchange on which registered) COMMON STOCK, NO PAR VALUE BOSTON STOCK EXCHANGE Securities registered under Section 12(g) of the Exchange Act: (Title of each class) COMMON STOCK, NO PAR VALUE Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days YES [X] NO [ ] Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-K is not contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ] As of March 31, 2000, the aggregate market value of the Registrant's Common Stock held by non-affiliates, based upon the average bid and asked price as of such date, was $149,306,685. There were 17,988,686 shares of the Registrant's Common Stock issued and outstanding as of March 31, 2000. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant's Definitive Proxy Statement for the 2000 Annual Meeting of Shareholders to be held on June 5, 2000, are incorporated by reference in Part III hereof. ITEM 1. DESCRIPTION OF BUSINESS CERTAIN STATEMENTS CONTAINED IN THIS FORM 10-K ARE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF THE SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED AND SECTION 21E OF THE EXCHANGE ACT OF 1934, AS AMENDED. SPECIFICALLY, ALL STATEMENTS OTHER THAN STATEMENTS OF HISTORICAL FACT INCLUDED IN THIS FORM 10-K REGARDING THE COMPANY'S FINANCIAL POSITION, BUSINESS STRATEGY AND PLANS AND OBJECTIVES OF MANAGEMENT OF THE COMPANY FOR FUTURE OPERATIONS ARE FORWARD-LOOKING STATEMENTS. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF THE COMPANY'S MANAGEMENT, AS WELL AS ASSUMPTIONS MADE BY AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT. WHEN USED IN THIS REPORT, THE WORDS "ANTICIPATE," "BELIEVE," "ESTIMATE," "EXPECT" AND "INTEND" AND WORDS OR PHRASES OF SIMILAR IMPORT, AS THEY RELATE TO THE COMPANY OR ITS SUBSIDIARIES OR COMPANY MANAGEMENT, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH STATEMENTS REFLECT THE CURRENT VIEW OF THE COMPANY WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO CERTAIN RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATED TO CERTAIN FACTORS INCLUDING, WITHOUT LIMITATION, COMPETITIVE FACTORS, GENERAL ECONOMIC CONDITIONS, CUSTOMER RELATIONS, RELATIONSHIPS WITH VENDORS, THE INTEREST RATE ENVIRONMENT, GOVERNMENTAL REGULATION AND SUPERVISION, PRODUCT INTRODUCTIONS AND ACCEPTANCE, TECHNOLOGICAL CHANGE, CHANGES IN INDUSTRY PRACTICES, ONETIME EVENTS AND OTHER FACTORS DESCRIBED HEREIN AND IN THE COMPANY'S REGISTRATION STATEMENT ON FORM S-3, AS AMENDED (FILE NO. 333-83631), AND IN THE COMPANY'S ANNUAL, QUARTERLY AND OTHER REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (COLLECTIVELY, "CAUTIONARY STATEMENTS"). ALTHOUGH THE COMPANY BELIEVES THAT ITS EXPECTATIONS ARE REASONABLE, IT CAN GIVE NO ASSURANCE THAT SUCH EXPECTATIONS WILL PROVE TO BE CORRECT. BASED UPON CHANGING CONDITIONS, SHOULD ANY ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALIZE, OR SHOULD ANY UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY VARY MATERIALLY FROM THOSE DESCRIBED HEREIN AS ANTICIPATED, BELIEVED, ESTIMATED, EXPECTED, OR INTENDED. ALL SUBSEQUENT WRITTEN AND ORAL FORWARD-LOOKING STATEMENTS ATTRIBUTABLE TO THE COMPANY OR PERSONS ACTING ON ITS BEHALF ARE EXPRESSLY QUALIFIED IN THEIR ENTIRETY BY THE APPLICABLE CAUTIONARY STATEMENTS. THE COMPANY DOES NOT INTEND TO UPDATE THESE FORWARD-LOOKING STATEMENTS. PROSPECTIVE INVESTORS ARE ADVISED NOT TO RELY UPON FORWARD-LOOKING STATEMENTS, BUT RATHER BASE THEIR INVESTMENT DECISION ON THE COMPANY'S ACTUAL RESULTS TO DATE. THE COMPANY OVERVIEW Interleukin Genetics, Inc., a Texas corporation ("ILGN" or the "Company"), develops and commercializes genetic diagnostic tests and medical research tools. The Company's efforts are focused on genetic factors that affect the rate of progression of clinical disease through their influence on common host systems. The Company's first genetic test, PST(R), a test predictive of risk for periodontal disease, is currently marketed in the United States, Europe and Israel. Products under development include tests predictive of risk for osteoporosis, coronary artery disease, diabetic retinopathy, asthma, pulmonary fibrosis and meningitis/sepsis. The Company believes by combining genetic risk assessment with specific therapeutic strategies, improved clinical outcomes and more cost-effective management of these common diseases may be achieved. ILGN also develops and licenses its medical research tools, including BioFusion(R), to pharmaceutical companies. BioFusion, a proprietary enabling system for diagnostic and drug discovery and development, is a computer modeling system that integrates genetic and other sub-cellular behavior, system functions, and clinical symptoms to simulate complex diseases. This system allows useful information to be derived from rapidly increasing databases of gene expression being generated in companies and academic centers worldwide. ILGN's executive offices are located at 100 N.E. Loop 410, Suite 820, San Antonio, Texas 78216, and its telephone number is 210/349-6400. ILGN was incorporated in Texas in 1986. ILGN maintains a website at www.ilgenetics.com. In November 1997 ILGN completed an initial public offering of 1,800,000 shares of common stock, no par value ("Common Stock"). In August 1999, the shareholders of the Company approved the name change of the Company from Medical Science Systems, Inc. to Interleukin Genetics, Inc. -1- Management believes the new name reflects the Company's focus on the interleukin area of the human genome. On March 31, 2000, the closing bid price of the Common Stock on the NASDAQ SmallCap Market was $10.06 per share. CURRENT FINANCIAL CONDITION Since its inception, the Company has incurred cumulative net losses of approximately $21 million, including losses of approximately $6.1 million, $9.5 million and $4.5 million during 1999, 1998 and 1997, respectively. For the years ended December 31, 1999, 1998, and 1997 the Company had negative cash flows from operating activities of approximately $4.4 million, $8.5 million, and $3.4 million, respectively. As a result of these losses, available cash resources are limited and will be depleted in September 2001 absent additional debt, equity funding and/or growth in revenue. In January 2000, the Company sold 832,667 shares of Common Stock in a private placement. The Company received net proceeds of approximately $4.7 million from this private placement. In June 1999, the Company completed a private placement of 2,200,000 shares of Series A Preferred Stock, no par value ("Series A Preferred"). The Company received net proceeds of approximately $4.7 million from this private placement. Following approval of this private placement by the Company's shareholders on August 20, 1999, all of the issued and outstanding shares of Series A Preferred converted into 11,000,000 shares of Common Stock. STRATEGY ILGN's objective is to be a leading genetics research and development company focused on the discovery and development of diagnostic tests and medical research tools. ILGN's strategy is to develop products for research and clinical use that are commercialized through strategic collaborations. These products include tests that are predictive of disease risk and tools for use in drug development. The Company believes that it will, in the near term, generate testing revenues, licensing fees, research and development funding, and fee-for-service or participatory revenues pursuant to contracts with its collaborative partners. In the long term, the Company believes it will generate royalty payments from its corporate partners for new genetic tests and therapeutic products. The Company believes that this strategy allows the Company to generate near-term revenues and diversify risk, while building a proprietary product portfolio with significant long-term potential. One of the Company's core strengths is its ability to identify genetic variations or markers which correlate with an individual's predisposition to a wide range of common chronic diseases. DEVELOPMENT SYSTEM AND APPROACH Many factors, both environmental and genetic, contribute to most common diseases. Importantly, some genetic factors are sufficiently strong that they influence the onset and progression of a disease despite many other variables. These genetic factors control aspects of the biology that have high leverage on the disease. The Company has focused its research and product development efforts on genetic factors that significantly influence the clinical course of common, chronic diseases. The Company's development program uses a proprietary enabling system called BioFusion. BioFusion is a computer modeling system that integrates genetic and other biological information to identify specific molecules or biochemical pathways that have large magnitude effects on the progression of disease and clinical outcomes. The Company then conducts clinical and basic biological studies to test hypotheses generated by the modeling system. -2- Using this approach, the Company has demonstrated that certain genetic factors are significant determinants of the clinical expression of multiple common diseases. These factors affect the severity and the rate of progression of clinical disease through their influence on host systems that are common to several disease processes. A person who possesses the genetic marker (referred to as a "genotype-positive individual) translates a disease challenge into a higher clinical disease trajectory (more rapid progression of the disease) than a genotype-negative individual with a comparable disease challenge. PRODUCT PIPELINE AND PROPRIETARY POSITION The Company has completed clinical trials and patent applications have been filed or patents have been issued on the role of genetic factors in the following diseases: o Periodontitis (patent issued) o Osteoporosis (patent issued) o Coronary artery disease (patent pending) o Diabetic retinopathy (patent pending) o Meningitis/Sepsis (patent pending) o Asthma (patent pending) o Pulmonary Fibrosis (patent pending) o Low Birth Weight (patent pending) Based on these discoveries, the Company is developing a pipeline of tests that are predictive of disease risk. Under development are tests predictive of the disease risk for osteoporosis, coronary artery disease, diabetic retinopathy (blindness associated with diabetes), asthma, pulmonary fibrosis and meningitis/sepsis. PST, a test predictive of disease risk for periodontitis (gum disease), was introduced commercially in the U.S. in the fourth quarter of 1997. The Company considers several factors in determining whether to pursue new genetic testing programs, including projected commercial potential, effectiveness of current therapies and the status of competitive programs, likelihood of attracting collaborators, and anticipated development costs. In each clinical disease field, the Company's development program is focused on understanding how genetic risk factors relate to overall risk for the disease and establishing clear links to treatment. By combining genetic risk assessment with specific therapeutic strategies, the Company believes improved clinical outcomes and more cost-effective management of these common diseases can be achieved. These genetic factors are also of value in both identifying response patterns during clinical trials for the enhancement of existing therapeutic agents and for developing new therapeutics directed at specific immuno-inflammatory components of several common diseases. CLINICAL UTILITY The Company believes in the advantages a genetic approach to medicine offers in the prevention, management and treatment of disease. The Company believes its predictive tests and research tools are of value to: o Pharmaceutical companies, who may use them to speed new drug development, to improve the efficacy of their drugs, and to develop new therapeutics. o Payors and organizations who provide health care services, who may use them to stratify patients by risk and more effectively allocate resources for the greatest benefit. o Physicians and other healthcare professionals, who may use this information to assess the risk involved for their patients and adopt appropriate treatments or preventive strategies. -3- o Patients committed to staying healthy, who may use this information to make better choices and set priorities based on personal knowledge of their individual risk for common diseases. TEST PREDICTIVE OF DISEASE RISK FOR PERIODONTAL DISEASE. The Company's first genetic susceptibility test, PST, detects a genetic susceptibility to severe gum disease (periodontitis). Periodontitis is a bacterially-induced chronic inflammation that destroys the collagen fibers and bone that surround and support the teeth. Untreated, periodontitis will eventually result in tooth loss. Individuals who test positive for this genotype will normally be placed on a more frequent recall program with their dental provider, and would be candidates for more aggressive treatment. The PST is the result of a scientific breakthrough in which an association was discovered between a specific IL-1 genotype and severe periodontal disease. IL-1 is a cytokine or protein that is known to play a role in inflammation and the expression of periodontal disease. Patients with this specific genotype have been found to progress more rapidly towards severe periodontal disease. It has also been determined that cells with this genotype produce as much as four times more IL-1 in response to the same bacterial challenge. Prevention or therapeutic intervention aimed at reducing the bacterial challenge should decrease the stimulus for IL-1 production and thereby protect the patient against the potentially destructive effects of this genotype. It is estimated that approximately 30% of the population will test positive for this genotype. The Company has developed PST pursuant to a project agreement between the Company and Sheffield University. In November, 1997, a patent related to the detection of genetic predisposition to periodontal disease was issued to the Company. The Company initiated commercial sales of PST in October 1997. In December 1998, the Company entered into an agreement with Washington Dental Service, a member of Delta Dental Plans Association, for the purchase of 1,200 PST tests to be used in a study sponsored by Washington Dental Service, in collaboration with the University of Washington School of Dentistry and ILGN. The study is designed to quantify the relationship between PST genotype status and the utilization of dental services by patients in a dental plan. The study, which began in early 1999, will provide scientific and financial information about PST in a reimbursement system. If patients who are at increased risk for periodontal disease can be identified early using PST, services can be provided which should minimize the progression of disease and the cost and complications of its consequences. The most costly dental procedures are usually those associated with tooth loss due to advanced disease (i.e., bridges, partial dentures, implants, etc.). Therefore, early identification and intervention of high-risk patients is in the patients' and payer's best interest. The Company believes that the results of this study will provide important scientific and financial data regarding the use of PST as a treatment- planning tool to assess risk before actual damage occurs. The data from the study may be available for analysis in early 2001. In September 1999, the Company introduced a saliva-based PST test which replaces the Company's blood-based PST test. The Company has entered into agreements for PST to be marketed in North America, Europe and Israel. TEST PREDICTIVE OF DISEASE RISK FOR OSTEOPOROSIS. Osteoporosis, the most common bone disease, results in a decrease in the amount of normal bone which leaves the affected individual more susceptible to fractures. The Company has identified a genetic marker that in clinical trials was associated with a more rapid loss of bone in women after menopause. -4- The clinical utility of the Company's osteoporosis susceptibility test lies in its ability to predict a patient's future bone density trend. A genotype positive test result is a significant risk factor for accelerated bone loss after menopause. A positive patient is more likely to exhibit low bone mineral density and experience severe fractures compared to a genotype negative patient. Early patient identification and appropriate intervention can alter the rate of the disease. The Company's test provides data that will allow practitioners to practice preventive medicine. Results of this test will assist women who are approaching menopause in deciding whether to start treatment. This will enable counseling at a sufficiently early stage in the process that significant bone loss can be avoided through lifestyle modification and/or drug/hormone therapy. During 1999, the Company completed a large scale clinical trial on its osteoporosis test. The data from this trial confirms that the Company's genetic factors are associated with an increase in risk of osteoporosis in genotype-positive persons compared to genotype negative persons. TEST PREDICTIVE OF DISEASE RISK FOR CORONARY ARTERY DISEASE (Patent Pending). The Company's coronary artery disease test (the "CAD test") is a genetic test capable of detecting those individuals with a significantly higher level of susceptibility to coronary artery disease. This genetic marker can be combined with other risk factors to identify individuals at high risk for developing a more rapidly progressive and severe form of coronary artery disease. The availability of the Company's CAD test will provide practitioners with a means of truly practicing preventive medicine with respect to coronary artery disease. The CAD test can be given to all individuals early in life because genetic risk factors do not change over time. Individuals who test positive for the genotype can be treated with more aggressive approaches to risk factor reduction. As these individuals age, they can be provided with more regular: (i) monitoring of cholesterol levels; (ii) blood pressure testing; and (iii) early intervention to alter the level of blood lipids (I.E., fats). Such an approach allows for truly preventive medicine through early risk factor reduction and appropriate monitoring for early detection of any problems. During 1999, the Company completed two large-scale clinical trials. The data from these trials confirms that individuals with the IL-1 genetic marker have an increased risk for heart disease even if such individuals do not have high cholesterol. These findings are significant as over half of the first heart attacks occur in individuals who cannot be identified using traditional risk factors, such as smoking, high cholesterol, and diabetes. Genetic factors that are independent of cholesterol may be of importance in identifying new populations at increased risk for early heart disease. Once identified, these individuals may reduce that risk by lowering cholesterol levels, even when the cholesterol levels would not be considered "high" by currently accepted norms. These factors may also provide new approaches to prevention and therapy. TEST PREDICTIVE OF DISEASE RISK FOR RETINOPATHY IN DIABETICS (Patent Pending). Another genetic susceptibility test, which is currently being developed by the Company, is a test to determine the susceptibility to sight-threatening retinopathy in diabetics. This susceptibility involves a continued and increased risk of losing vision when an individual has been diagnosed with diabetes. The Company has identified a genetic marker that is correlated with an increased risk of developing diabetic retinopathy in patients who have diabetes. This correlation seems to indicate an earlier onset of retinopathy in patients who have diabetes thus putting such individuals at risk of losing their sight at an earlier age. The availability of such a test would allow practitioners to assess a patient's risk of losing his or her sight due to diabetes at the time that he or she is diagnosed with the disease. Preventive treatment would allow doctors to practice truly preventive medicine, providing a means of identifying susceptible patients early in -5- the disease process. Enhanced assessment and monitoring can then be initiated from the start, allowing early detection of problems and preemptive treatment that will ultimately reduce the incidence of diabetes related vision loss. This would translate into improvements in patient quality of life and cost savings. To date, the Company has completed an initial study involving 500 patients who demonstrated a strong association between specific genetic markers and susceptibility to diabetic retinopathy. TESTING PROCEDURE Each of the Company's genetic susceptibility tests requires, or will require, that a single procedure be utilized. To conduct a genetic susceptibility test, the doctor draws a blood or saliva sample and submits it to the Company's customer service department. The customer service department then logs in the sample and submits sample batches to the ILGN laboratory or reference lab for testing. The laboratory then performs the test following the Company's specific protocol and informs the Company of the results. The Company, in turn, advises the doctor of the results, who informs the patient and determines the appropriate course of action. At the time results are provided to the doctor, the Company's billing service will invoice the patient directly for the test. The doctor will then invoice the patient for his or her professional services related to administration of the test. The Company will continue to use one or more sophisticated, certified, and fully validated laboratories capable of providing consistent and high quality analysis. Customer service is handled via the Company's toll free "888" numbers by the Company's own staff who are knowledgeable about its genetic susceptibility tests, the procedural requirements of the testing system and the related diseases. In the future, the Company may license the right to market and perform the testing services to collaborative partners in exchange for a royalty or other payments. PRE-MARKETING TRIALS/STATUS OF PREDICTIVE TESTS As an internal procedural standard, the Company conducts three categories of clinical trials in conjunction with its genetic susceptibility tests. The first trial is called a proof of principle trial, used to prove a laboratory finding. The results of this trial are utilized to support the initial patent application and therefore need to be completed before the patent application can be filed. The second trial is a confirmatory trial. The purpose of the confirmatory trial is to independently confirm the results of the proof of principle trial. The third category of trial relates to clinical utility. The clinical utility trial is conducted to learn what is the most effective utilization of the test in actual clinical practice. Following confirmatory studies, additional trials are completed on larger populations to help develop broad scientific evidence supporting the clinical utility of each of the Company's tests. Such additional trials not only strengthen the support for each tests' known use (I.E., detecting genetic susceptibility) but also lead to additional practical uses of the susceptibility tests (E.G., use of the susceptibility tests to determine a patient's responsiveness to a given drug). PRODUCT DEVELOPMENT The Company has ongoing research to continue to identify other genetic factors that appear to be associated with other diseases. The Company plans on filing additional patent applications to cover these discoveries. It is the Company's intent to bring these discoveries to market in the form of tests predictive of disease risk or medical research tools. The Company has also come upon certain genetic factors that might be likely candidates to serve as therapeutic targets, those susceptible to influence by drug agents. The Company is considering certain collaborative long term relationships with pharmaceutical companies as a -6- method to provide for either the licensing of its discoveries or to assist in the research and development of future products. STRATEGIC ALLIANCES AND COLLABORATIONS The Company's strategy is to develop products for research and clinical use and commercialize such products through strategic alliances. The Company has followed a strategy of working with strategic partners at the fundamental discovery stage. This strategy has given the Company access to discoveries while reducing up-front research expenses. SHEFFIELD UNIVERSITY Since 1994, the Company has had a strategic alliance with the Department of Molecular and Genetic Medicine at Sheffield University in the United Kingdom ("Sheffield"). Sheffield is a world leader in the genetic aspects of common diseases with an inflammatory component. Under this alliance, Sheffield has provided to the Company the fundamental discovery and genetic analysis from Sheffield's research laboratories and the Company has focused on product development, including clinical trials, and the commercialization of these discoveries. See "Factors Affecting Future Performance - Reliance on Collaborative Partners." In October 1999 the Company entered into a new arrangement with Sheffield and its investigators replacing the research and development agreement that had been in place with Sheffield since 1996. Pursuant to this new arrangement, the Company issued an aggregate of 475,000 shares of its Common Stock to Sheffield and certain of its investigators in exchange for the relinquishment by Sheffield of its net proceeds interests under certain agreements with the Company. GLAXO WELLCOME The Company has entered into a development and license agreement with Glaxo Wellcome to develop a computer model in support of new compound screening. ILGN's BioFusion proprietary technology provides a means of developing computer-based simulation models of large, complex biological systems, which can assist in the interpretation of gene expression and molecular screening databases. The computer models can be used for a number of purposes, including identifying new biologic targets for drug or diagnostic discovery, understanding how genetic discoveries influence disease, and clinical trial design. The Company has utilized this technology to support the development and commercialization of its genetic tests and in support of drug development efforts for large pharmaceutical companies. DELTA DENTAL The Company signed an agreement with Washington Dental Service, a member of the Delta Dental Plans Association, for the purchase of 1,200 PST tests. PST is the Company's test predictive of disease risk for periodontal disease (gum disease). The tests will be used in a study, sponsored by Washington Dental Service, in collaboration with the University of Washington School of Dentistry and Medical Science Systems. The study is designed to quantify the relationship between PST genotype status and the utilization of dental services by patients in a dental plan. The study, began in March 1999, is expected to provide scientific and financial information about PST in a reimbursement system. This study is also expected to provide scientific and financial data regarding the use of PST as a treatment-planning tool to assess risk. The study is expected to be completed by the end of 2000. See "Factors Affecting Future Performance - Reliance on Collaborative Partners." -7- PST COMMERCIAL PARTNERSHIPS In December 1997, the Company entered into an agreement with Medicadent, a French corporation ("Medicadent"), to market and sell PST in France. In August 1998, the Company entered into an agreement with H.A. Systems, Ltd. to market and sell PST in Israel. Medicadent commenced offering PST in France in June 1998, and H.A. Systems commenced offering PST in Israel in early 1999. In March 1999, the Company entered into an agreement with the Straumann Company to market and sell PST in the United States and Puerto Rico. Straumann launched its PST promotional activities in April 1999. In April 1999, the Company entered into an agreement with Dumex, a subsidiary of AlPharma, a pharmaceutical manufacturer, to market and sell PST in ten European countries (Austria, Denmark, Portugal, Finland, Germany, Ireland, Norway, Sweden, Switzerland and the U.K.). Dumex is well known in Europe as a manufacturer of oral health care products used by periodontists. No assurances can be made regarding the commercial acceptance of PST. INTELLECTUAL PROPERTY The Company's commercial success will be dependent in part on its ability to obtain patent protection on genes, genetic sequences and/or their relationship to common diseases, as well as diagnostic and therapeutic products and methods based on the association between particular genes and diseases, discovered by the Company and Sheffield University. The Company has a total of four issued U.S. patents and 16 pending U.S. patent applications. Of the four issued patents, two relate to the Company's genetic tests and two relate to BioFusion, the Company's biologic modeling software. The U.S. Patent and Trademark Office issued patents for the Company's periodontal and osteoporosis tests in November and December, 1997, respectively. The Company has been granted a number of corresponding foreign patents and has filed foreign counterparts of its U.S. applications within the appropriate time frames. Where the Company has originally filed in another country, it has filed and plans to continue to file U.S. and other foreign counterparts within the appropriate time frame. These applications seek to protect these gene markers and corresponding use of gene markers, and products derived therefrom and uses therefor. The Company is continuing to identify and develop applications related to additional genetic markers. The Company has also applied for trademark protection for the name of its periodontal susceptibility test. The Company's proprietary technology is subject to numerous risks. See "Factors Affecting Future Performance." COMPETITION Competition in the Company's potential markets is intense. Although testing for major genetic defects, such as Down's Syndrome, has been available for years, genetic susceptibility testing for multi- factorial diseases is a newly emerging growth segment. Despite this segment's relatively young age, other companies do exist which have research programs seeking disease related genes for therapeutic and susceptibility testing purposes, including some that involve treatable/ preventable disease. The technologies for discovering genes which predispose individuals to major diseases and approaches for commercializing those discoveries are new and rapidly evolving. Rapid technological developments could result in the Company's potential services, products, or processes becoming obsolete before the Company recovers a significant portion of its related research and development costs and capital expenditures associated therewith. Competitors of the Company in the United States and abroad are numerous and include, among others, major pharmaceutical and diagnostic companies, specialized biotechnology firms, universities and other research institutions, including those receiving funding from the Human Genome Project. Other companies with research programs include Myriad Genetics, Inc. ("Myriad") and Genome Therapeutics Corp. ("GTC"). GTC has announced that it has research programs focusing on osteoporosis. Myriad has a test for breast cancer -8- and has announced research programs for osteoporosis and coronary artery disease. Many of the Company's other potential competitors have considerably greater financial, technical, marketing and other resources than the Company, which may allow these competitors to discover important genes in advance of the Company. If the Company does not discover disease-predisposing genes, characterize their functions, develop genetic tests and related information services based on such discoveries, obtain regulatory and other approvals, and launch such services or products before competitors, the Company could be adversely affected. Additionally, some of the Company's competitors receive data and funding from the Human Genome Project. The Human Genome Program is a federally funded program focused on sequencing the human DNA and enriching the sequence data with information about its biological function. To the extent the Company's competitors receive data and funding from the Human Genome Project at no cost to them, they may have a competitive advantage over the Company. In the case of newly introduced products requiring "change of behavior," (such as genetic susceptibility tests) multiple competitors may accelerate market acceptance and penetration through increasing awareness. Moreover, two different genetic susceptibility tests for the same disease may in fact test or measure different components, and thus actually be complementary when given in parallel as an overall assessment of risk, rather than being competitive with each other. Furthermore, the primary focus of each of the above-referenced companies is performing gene- identifying research for pharmaceutical companies for therapeutic purposes, with genetic susceptibility testing being a secondary goal. On the other hand, the Company's primary business focus is developing and commercializing genetic susceptibility tests for common diseases, with only an ancillary drug discovery program. GOVERNMENT REGULATION The sampling of blood, saliva or cheek scrapings from patients and subsequent analysis in a clinical laboratory does not, at the present time, require Federal Drug Administration ("FDA") or regulatory authority approval inside the U.S. for either the sampling procedure or the analysis itself. The samples are taken in the healthcare provider's office, using standard materials previously approved as medical devices, such as sterile lancets and swabs. The testing procedure itself is performed in one or more registered, certified clinical laboratories under the auspices of the Clinical Laboratory Improvement Act of 1988 ("CLIA"), administered by the Health Care Financing Administration. The federal regulations governing approval of the laboratory facilities and applicable state and local regulations governing the operation of clinical laboratories would also apply to the laboratories performing tests for the Company. Changes in such regulatory schemes could require advance regulatory approval of genetic susceptibility tests sometime in the future and could have a material adverse effect on the Company's business. In addition, certain billing practices of the Company required it, or a subsidiary, to be licensed and regulated under CLIA. In addition, while the Company's main focus is on genetic susceptibility testing, the Company may, in the future, endeavor to partner with pharmaceutical companies in the area of drug development. Any drug products developed by the Company or the Company's future collaborative partners, prior to marketing in the United States, would be required to undergo an extensive regulatory approval process by the FDA. The regulatory process, which includes preclinical testing and clinical trials of each therapeutic product in order to establish its safety and efficacy, can take many years and requires the expenditure of substantial resources. Data obtained from preclinical and clinical activities are susceptible to varying interpretations which could delay, limit or prevent regulatory agency approval. In addition, delays or rejections may be encountered during the period of therapeutic development, including delays during the period of review of any application. Delays in obtaining regulatory approvals could adversely affect the marketing of any therapeutics developed by the Company or its collaborative partners, impose costly procedures upon the Company and its collaborative -9- partners' activities, diminish any competitive advantages that the Company or its collaborative partners may attain and adversely affect its ability to receive royalties. Once regulatory approval of a product is granted, such approval may impose limitations on the indicated uses for which it may be marketed. Further, even if such regulatory approval is obtained, a marketed product and its manufacturer are subject to continuing review. The discovery of previously unknown problems with a product or manufacturer may result in restrictions on such product or manufacturer. Such restriction could include withdrawal of the product from the market. EMPLOYEES As of March 31, 2000, the Company had 13 full-time employees. Of the Company's employees, 77% are engaged directly in the development and commercialization of tests and 23% are engaged in administrative or managerial activities. The Company's employees are not covered by a collective bargaining agreement, and the Company considers its relations with its employees to be good. FACTORS AFFECTING FUTURE PERFORMANCE NO ASSURANCE OF ADDITIONAL NECESSARY CAPITAL The Company anticipates that its current financial resources will be adequate to maintain its current and planned operations through September 2001. THERE CAN BE NO ASSURANCE THAT THE COMPANY WILL BE ABLE TO RAISE ANY ADDITIONAL NECESSARY CAPITAL. IF ADDITIONAL AMOUNTS CANNOT BE RAISED, THE COMPANY WOULD SUFFER MATERIAL ADVERSE CONSEQUENCES TO ITS BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS AND WOULD LIKELY BE REQUIRED TO SEEK PROTECTION UNDER THE UNITED STATES BANKRUPTCY LAWS. The Company's future capital requirements will depend on many factors, including successful expansion of sales of PST(R), the Company's genetic test for periodontal disease, and continued scientific progress with its research and development programs. The continuation of the Company's research and development activities may require substantial additional capital from private or public sources. There is no assurance that such capital will be available to the Company on acceptable terms. Furthermore, the market for publicly-traded stocks of biotechnology companies has historically been volatile, and the competition for equity capital from public and private sources is intense among the over 1,000 biotechnology companies in the United States that are dependent on infusions of capital to fund their operations. The Company is also engaged from time to time in discussions with several companies concerning the licensing of certain of the Company's proprietary technologies or forming strategic alliances, which could provide additional sources of funding to the Company as well as a possible source of equity capital. The Company is unable to predict the likelihood of completing any such arrangements. There can be no assurance that the Company will be successful in obtaining additional capital in amounts sufficient to continue to fund its operations and product development. INABILITY TO FULLY USE NET OPERATING LOSS CARRYFORWARDS As of December 31, 1999, and 1998 the Company had net operating loss carryforwards and a research tax credit of approximately $18,750,000 and $187,000, respectively, for federal income tax purposes, expiring in varying amounts through the year 2019. The Company's ability to use its NOL and credit carryforwards to reduce future taxes is subject to Section 382 of the Internal Revenue Code of 1986 (the "Code"). These restrictions provide for limitations on the Company's utilization of its NOL and credit carryforwards following a greater than 50% ownership change during the prescribed testing period. As of December 31, 1999, the Company had incurred such a change. As a result, approximately $15,619,000 of the Company's NOL -10- carryforwards are limited in utilization to approximately $825,000 annually. The annual limitation may result in the expiration of the carryforwards prior to utilization. UNCERTAINTY OF MARKET ACCEPTANCE FOR GENETIC SUSCEPTIBILITY TESTS The commercial success of the Company's genetic susceptibility tests and those that it may develop will depend upon their acceptance as medically useful and cost-effective by patients, physicians, dentists, other members of the medical and dental community and insurers. Broad market acceptance can be achieved only with substantial education about the benefits and limitations of such tests. It is uncertain whether current genetic susceptibility tests or others that the Company may develop will gain market acceptance on a timely basis. If patients, dentists and physicians do not accept the Company's tests, or take a longer time to accept than the Company anticipates, then the Company's revenues and profit margins may be reduced and may result in losses. DIFFICULTY OF DEVELOPING GENETIC SUSCEPTIBILITY TESTS It is uncertain whether the Company will be successful in developing and bringing to market its current portfolio or future tests based on the genetic discoveries made by the Company and its collaborators. Even when the Company discovers a genetic marker (I.E., a genetic variation or polymorphism associated with increased disease incidence or severity), additional clinical trials need to be conducted to confirm the initial scientific discovery and to support the scientific discovery's clinical utility in the marketplace. The results of a clinical trial could delay, reduce the test's acceptance or cause the Company to cancel a program. Such delays, reduced acceptance or cancellations would reduce revenues and may result in losses. HISTORY OF OPERATING LOSSES; ACCUMULATED DEFICIT; UNCERTAINTY OF FUTURE PROFITABILITY The Company incurred a net operating loss of $6,138,603 in 1999, $9,508,275 in 1998 and $4,494,062 in fiscal year 1997. As of December 31, 1999, our accumulated deficit was $21,012,188. The losses have resulted principally from expenses incurred in research and development and from selling, general and administrative expenses. These expenses have exceeded revenues. The Company has yet to generate any significant revenues from the sale of genetic susceptibility testing services and there can be no assurance that it will be able to generate significant revenues in the future. The Company expects operating losses to continue for the near future as research and development, sales and marketing activities and operations continue. The ability to achieve profitability depends on the ability to develop a sales and marketing capacity and to successfully market and sell products and services. It is uncertain when the Company will become profitable. UNCERTAINTY OF INSURANCE REIMBURSEMENT The Company's ability to successfully commercialize existing genetic susceptibility tests and others that the Company may develop depends in part on obtaining adequate reimbursement for such testing services and related treatments from government and private health care insurers (including health maintenance organizations) and other third-party payors. Physicians' and dentists' decisions to recommend genetic susceptibility tests, as well as patients' elections to pursue testing, are likely to be heavily influenced by the scope and extent of reimbursement for such tests by third-party payors. Government and private third-party payors are increasingly attempting to contain health care costs by limiting both the extent of coverage and the reimbursement rate for new testing and treatment products and services. In particular, services which are determined to be investigational in nature or which are not considered "reasonable and necessary" for diagnosis or treatment may be denied reimbursement coverage. To date, few insurers or third-party payors have agreed to reimburse patients for genetic susceptibility tests. As a result, the Company initially expects to bill patients directly for the genetic susceptibility tests. -11- It remains uncertain whether insurers or third-party payors will elect to provide full reimbursement coverage for the genetic susceptibility tests in the near future. If adequate reimbursement coverage is not available from insurers or third-party payors, it is uncertain whether individuals will elect to directly pay for the test. If both insurers or third-party payors and individuals are unwilling to pay for the test, then the number of tests performed will be significantly decreased. Such a scenario would result in reduced revenues and possible losses. RELIANCE ON COLLABORATIVE PARTNERS In October 1999, the Company entered into a new contractual arrangement with the University of Sheffield ("Sheffield") replacing the research and development agreement that had been in place since 1996. Under this new arrangement, the Company will undertake the development and commercialization of certain discoveries resulting from Sheffield's research. This agreement with Sheffield has a five-year term with an automatic yearly renewal. Pursuant to this new arrangement, the Company issued an aggregate of 475,000 shares of its Common Stock to Sheffield and its investigators in exchange for the transfer of certain patent rights and the relinquishment of proceeds interests held by Sheffield and its investigators under all project agreements. The Company also entered into a research and development services agreement with Sheffield which automatically renews in one-year increments. In connection with this new arrangement, the Company entered into a five-year consulting agreement with Sheffield's key collaborator. The Company anticipates entering into additional collaborative arrangements with Sheffield and other parties in the future. In the future the Company may, in order to facilitate the sale of testing services and/or products, enter into collaborative selling arrangements with one or more other persons. It is uncertain whether the Company will be able to negotiate acceptable collaborative arrangements in the future or that such collaborative arrangements will be successful. If the Company is unable to identify collaborative partners to sell certain of our services and/or products, it may be forced to develop an internal sales force to market and sell its services and/or products in markets where it is not intending on developing a direct selling presence. Such a process would take more time and potentially cost more. As a result, revenues and earnings would be reduced. If the Company enters into collaborative selling arrangements, its success will depend upon the efforts of others and may be beyond its control. Failure of any collaborative selling arrangement could result in reduced revenues and possible losses. UNCERTAIN ABILITY TO PROTECT PROPRIETARY TECHNOLOGY The Company's success will partly depend on its ability to obtain patent protection, both in the United States and in other countries, for its products and services. In addition, the Company's success will also depend upon its ability to preserve its trade secrets and to operate without infringing the proprietary rights of third parties. The Company has sixteen (16) patent applications pending, including applications covering certain of its anticipated genetic susceptibility tests. There can be no assurance that the Company's patent applications will ever be issued as patents or that the claims of any issued patents will afford meaningful protection for the Company's technology or products. Further, others may develop similar products which test for susceptibility related to some diseases yet avoid infringing upon, or conflicting with, the Company's anticipated patents. In addition, there can be no assurance that any patents issued to the Company will not be challenged, and subsequently narrowed, invalidated or circumvented. The Company's testing services and/or products may also conflict with patents which have been or may be granted to others. As the biotechnology industry expands and more patents are filed and issued, the risk increases that the Company's products may give rise to a declaration of interference by the Patent and Trademark Office, or to claims of patent infringement by other companies, institutions or individuals. Such -12- entities or persons could bring legal proceedings against the Company seeking damages or seeking to enjoin the Company from testing, manufacturing or marketing its products. Patent litigation is costly, and even if the Company prevails, the cost of such litigation could have an adverse effect on the Company. If the other parties in any such actions are successful, in addition to any liability for damages, the Company could be required to cease the infringing activity or obtain a license. It is uncertain whether any license required would be available to the Company on acceptable terms, if at all. Failure by the Company to obtain a license to any technology that it may require to commercialize its products could have a material adverse effect on the Company's business, financial condition, results of operations and cash flows. In addition, there is considerable pressure on academic institutions and other entities to publish discoveries in the genetic field. Such a publication by an academic institution or other entity, prior to the Company's filing of a patent application on such discovery, may compromise the Company's ability to obtain U.S. and foreign patent protection for the discovery. The Company also relies upon unpatented proprietary technologies. The Company relies on confidentiality agreements with its employees, consultants and collaborative partners to protect such proprietary technology. There can be no assurance that the Company can adequately protect its rights in such unpatented proprietary technologies, that others will not independently develop substantially equivalent proprietary information or techniques, or otherwise gain access to the Company's proprietary technologies or disclose such technologies. The United States Patent and Trademark Office issued new Utility Guidelines in July 1995 that address the requirements for demonstrating utility, particularly in inventions relating to human therapeutics. While the guidelines do not require clinical efficacy data for issuance of patents for human therapeutics, there can be no assurance that the Patent and Trademark Office's interpretations of such guidelines, and any changes to such interpretations will not delay or adversely affect the Company's or the Company's collaborators' ability to obtain patent protection. The biotechnology patent situation outside the United States is even more uncertain and is currently undergoing review and revision in many countries. TECHNOLOGICAL CHANGES RESULTING IN PRODUCT OBSOLESCENCE Market acceptance and sales of the Company's testing services could also be adversely affected by technological change. It is uncertain whether the Company's competitors will succeed in developing genetic susceptibility tests that circumvent or are more effective than the Company's technologies or services. Further, it is uncertain whether such developments would render the Company's or the Company's collaborators' technology or services less competitive or obsolete. Further, the Company's testing services could be rendered obsolete as a result of future innovations in the treatment of gum disease, osteoporosis, coronary artery disease or diabetes retinopathy, which could have a significant negative impact on the Company's ability to market its services effectively. POSSIBLE NASDAQ DELISTING; LIMITED PUBLIC MARKET FOR COMMON STOCK; POSSIBLE VOLATILITY OF SECURITIES PRICES Our Common Stock is currently listed on The NASDAQ SmallCap Market and the Boston Stock Exchange. If the Company fails to maintain the qualification for its Common Stock to trade on the NASDAQ SmallCap Market or the Boston Stock Exchange, its Common Stock could be subject to delisting. The NASDAQ Stock Market, Inc. ("NASDAQ") announced increases in the quantitative standards, which became effective in February 1998, for maintenance of any of (x) $2,000,000 of net tangible assets, (y) $35,000,000 of market capitalization or (z) $500,000 of net income for two of the last three years and a minimum bid price per share of $1.00. On February 3, 1999, we received notice from NASDAQ that we were in violation of NASDAQ's minimum bid price requirement and that if our Common Stock does not have a closing bid price of at least $1.00 for ten consecutive trading days during the 90 day period ended May 3, 1999, our Common Stock will be subject to delisting on May 3, 1999. The Company believes it has satisfied this requirement by -13- having a closing bid price of at least $1.00 for each trading day since May 7, 1999; however the Company has not received notice from NASDAQ that such requirement was satisfied. Furthermore, there can be no assurance that our stock price will maintain such $1.00 minimum bid price. If the market price for our Common Stock does fall below the $1.00 bid price, our Common Stock could be subject to delisting from The NASDAQ SmallCap Market. On April 19, 1999, the Company received notice from the NASDAQ SmallCap Market that the Company was in violation of NASDAQ's $2,000,000 minimum net tangible asset requirement. As a result of the private placement completed in June 1999, management believes that the Company is in compliance with NASDAQ's minimum net tangible asset requirement; however, the Company has not received notice from NASDAQ that such requirement was satisfied. The Company filed a Current Report on Form 8-K dated June 25, 1999, containing the Company's pro forma balance sheet at May 31, 1999, adjusted to reflect the results of the June private placement. Such balance sheet reflects net tangible assets in excess of $2,000,000. If the Company is unable to maintain compliance with NASDAQ's minimum net tangible asset requirement, or maintain a $35,000,000 market capitalization, the Company would likely be delisted from the NASDAQ SmallCap Market and may also suffer material adverse consequences to its business, financial condition and results of operations. On August 3, 1999, the Company received a notice from NASDAQ questioning whether the Company had violated the shareholder approval provisions of the NASDAQ Marketplace Rules due to an alleged change- in-control resulting from the private placement of Series A Preferred Stock completed by the Company in June 1999. As a result, NASDAQ is reviewing the Company's eligibility for continued listing on the NASDAQ SmallCap Market. The Company does not believe that a change-of-control occurred and is engaged in discussions with NASDAQ to resolve this matter; however, as of March 1, 2000, the Company had not received notification of NASDAQ's decision regarding this matter. At the Annual Meeting held August 20, 1999, our shareholders ratified the private placement of Series A Preferred Stock. There can be no assurance that the Company will be able to address this issue in a manner satisfactory to NASDAQ, or that the Company's Common Stock will not be delisted from the NASDAQ SmallCap Market. If our shares are not listed as intended, trading, if any, would be conducted in the over-the-counter market in the so-called "pink sheets" or the OTC Bulletin Board, which was established for securities that do not meet the NASDAQ SmallCap Markets listing requirements. Consequently, selling our shares would be more difficult because smaller quantities of shares could be bought and sold, transactions could be delayed, and security analysts' and news media's coverage of our company may be reduced. These factors could result in lower prices and larger spreads in the bid and ask prices for our share. If our shares are not listed on the NASDAQ SmallCap Market and/or the Boston Stock Exchange, they may become subject to Rule 15g-9 under the Exchange Act. That rule imposes additional sales practice requirements on broker-dealers that sell low-priced securities to persons other than established customers and institutional accredited investors. For transactions covered by this rule, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. Consequently, the rule may affect the ability of broker-dealers to sell our shares and affect the ability of holders to sell our shares in the secondary market. The SEC's regulations define a "penny stock" to be any equity security that has a market price less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. The penny stock restrictions will not apply to our shares if they are listed on the NASDAQ SmallCap Market or the Boston Stock Exchange and we provide certain price and volume information on a current and continuing basis, or meet required minimum net tangible assets or average revenue criteria. We cannot assure you that our shares will qualify for exemption from these restrictions. If our shares were subject to the penny stock rules, the market liquidity for the shares could be adversely affected. -14- Historically, the Common Stock has experienced low trading volumes. The market price of the Common Stock also has been highly volatile and it may continue to be highly volatile as has been the case with the securities of other public biotechnology companies. Factors such as announcements by the Company or its competitors concerning technological innovations, new commercial products or procedures, proposed government regulations and developments or disputes relating to patents or proprietary rights may substantially affect the market price of the Company's securities. Changes in the market price of the Common Stock may bear no relation to the Company's actual operational or financial results. LIMITED MARKETING OR SALES EXPERIENCE Our business strategy is to provide genetic susceptibility testing services aimed at common diseases that are treatable and preventable. The commercial introduction of the periodontal susceptibility test at the beginning of October 1997 represented our first such effort. From its commercial inception through 1999, our periodontal susceptibility test has generated revenues of $866,726. With respect to the periodontal susceptibility test, we have devoted substantial human and financial resources to the establishment and staffing of a customer service support facility and the building of a sales and marketing infrastructure. However, we have limited experience in developing and commercially marketing susceptibility testing services. It is uncertain whether our customer service support facilities and sales and marketing program will achieve efficient, effective or successful operations. Failure to successfully market such tests could reduce our revenues and may result in losses. PRODUCT LIABILITY EXPOSURE Our business exposes us to potential liability risks inherent in the testing and marketing of medical and dental related services or products. It is uncertain whether liability claims will be asserted against us. We have product and professional liability insurance which we believe provides coverage for the testing and commercial introduction of our genetic susceptibility tests. It is uncertain whether we will be able to maintain such insurance on acceptable terms. Any insurance obtained may not provide adequate coverage against potential liabilities. A liability claim, even one without merit, could result in significant legal defense costs thereby increasing our expenses, lowering our earnings and even resulting in losses. ETHICAL, LEGAL AND SOCIAL IMPLICATIONS OF GENETIC TESTING The prospect of broadly available genetic testing has raised issues which are currently being widely discussed by the medical and scientific communities, as well as other interested groups and organizations, regarding the appropriate utilization and the confidentiality of information provided by such testing. The recent movement towards discovery and commercialization of susceptibility tests for assessing a person's likelihood of developing a chronic disease has also focused public and legislative attention on the need to protect the privacy of genetic assessment medical information. With the progression towards more comprehensive record keeping by health insurers and managed care firms, this need has led to a number of legal initiatives. The recently enacted federal health insurance reform law (Health Insurance Portability Act of 1996) recognizes the comparability of information obtained by genetic means to other types of personal medical information. The law prohibits insurance companies from refusing health insurance coverage to individuals on the basis of their medical history, including "genetic information." This legislation also prohibits employees from discrimination in hiring practices on the same basis. This legislation indicates a trend to protect the privacy of patients while allowing them to be screened for conditions which, can be prevented, reduced in severity or cured. In the most extreme scenario, governmental authorities could, for social or other purposes, limit the use of genetic testing or prohibit testing for genetic susceptibility to certain conditions. For these reasons, we could experience a delay or reduction in test acceptance. Such a delay or reduction could reduce our revenues or result in losses. -15- We are taking a proactive stance in the ethical arena. Our Chief Executive Officer, Dr. Philip Reilly, is both an M.D. (certified specialist in clinical genetics) and an attorney and is knowledgeable in the area of genetic testing and its ethical, legal and clinical utility ramifications. Additionally, we are currently advising doctors who administer our genetic susceptibility tests to take special efforts to maintain the confidentiality of the test results. Our intent is to avoid information about test results being disclosed to insurers until issues regarding insurability have been fully analyzed and acted upon by the appropriate legislative bodies. DEPENDENCE ON KEY PERSONNEL AND CONSULTANTS Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified management, scientific and technical personnel. Our company will also be dependent upon the ability to hire qualified marketing and sales personnel. Competition for scientific, marketing and sales personnel is intense. Loss of the services of Drs. Kornman or Reilly or Gordon Duff, a key researcher with the University of Sheffield, could adversely affect our research and development programs and susceptibility testing service business and could impede the achievement of our business objectives. We maintain key man life insurance on Drs. Kornman and Duff. ABSENCE OF DIVIDENDS We have never paid dividends and do not intend to pay any dividends in the foreseeable future. SHARES ELIGIBLE FOR FUTURE SALE Substantially all of the outstanding Common Stock is available for sale in the public marketplace. There are also outstanding stock options and warrants to purchase an aggregate of 3,258,675 shares of Common Stock at various exercise prices per share. No prediction can be made as to the effect, if any, that sales of shares of Common Stock or the availability of such shares for sale will have on the market prices prevailing from time to time. The possibility that substantial amounts of Common Stock may be sold in the public market may adversely affect prevailing market prices for the Common Stock, and could impair the Company's ability to raise capital through the sale of its equity securities. EFFECT OF PREFERRED STOCK AND DIRECTOR REMOVAL PROVISIONS Our Board of Directors is authorized to issue up to 5,000,000 shares of Preferred Stock and to determine the price, rights, preferences and privileges of those shares without any further vote or action by our shareholders. The rights of the holders of Common Stock will be subject to, and may be adversely affected by, the rights of the holders of any shares of Preferred Stock that may be issued in the future. While we have no present intention to issue shares of Preferred Stock, such issuance, while providing desirable flexibility in connection with possible acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire a majority of our outstanding voting stock. In addition, such Preferred Stock may have other rights, including economic rights, senior to the Common Stock. As a result, the issuance of Preferred Stock could decrease the market value of the Common Stock. Our Articles of Incorporation provide that members of the Board of Directors may be removed only for cause upon the affirmative vote of holders of at least a majority of the shares of our outstanding capital stock entitled to vote. Certain other provisions of our Articles of Incorporation could also have the effect of delaying or preventing changes of control or in management. Such a delay or preventive effect could adversely affect the price of our Common Stock. -16- ITEM 2. PROPERTIES The Company has two offices in the following locations: Flagstaff, Arizona and San Antonio, Texas. Flagstaff, Arizona is the site of the Company's global commercial operations, including its marketing, sales and customer service organization. The San Antonio Research Center is the principal site of its research and development and employs teams of top medical, dental and computer scientists. San Antonio is the site of its corporate headquarters. The Company's commercial operations office located at 3100 N. West Street, Bldg. A, Flagstaff, Arizona, contains 6,000 square feet and is held under a five year lease which expires in September 2002. The Company's corporate headquarters and research and development offices, located at 100 N.E. Loop 410, Suite 820, San Antonio, Texas, contain 8,131 usable square feet held under a lease expiring May 31, 2003. The Company's former corporate headquarters, located at 4400 MacArthur Boulevard, Suite 980, Newport Beach, California, contains 1,798 usable square feet and has been subleased by the Company until the expiration of the Company's original lease in April 2001. ITEM 3. LEGAL PROCEEDINGS On March 2, 1999, Entelos, Inc. filed an action against the Company in United States District Court for the Northern District of California, alleging that two of Entelos' principals, Samuel Holtzman and Thomas Paterson, are co-inventors of the inventions claimed in two of the Company's patents - U.S. Pat. Nos. 5,657,255 and 5,808,918, both of which relate to the Company's BioFusion products. In the suit, Entelos seeks a declaratory judgment that Entelos is the co-owner of all rights under the foregoing patents, an order correcting the inventorship of the patents to list Holtzman and Paterson as co-inventors, and restitution to Entelos of its share of the profits obtained from the patents. The complaint also asserted an unfair competition claim. In June 1999 the Company entered into a settlement agreement with Entelos, that, among other things, granted Entelos a non-exclusive, fully paid-up, royalty-free world-wide license to make, have made, use, import, offer to sell and sell products and practice any systems, methods or other inventions covered by the patents. Pursuant to a stipulation and order of dismissal issued by the United States District Court for the Northern District of California, all claims and counterclaims in the above-described action were dismissed with prejudice. The Company did not pay any money to Entelos as part of the agreement, and management does not believe that the settlement will have a material adverse effect on future business activities of the Company. ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS No matters were submitted during the fourth quarter of the year ended December 31, 1999. PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS MARKET INFORMATION The Company's Common Stock began trading on The NASDAQ SmallCap Market on November 26, 1997 under the symbol "MSSI" and on the Boston Stock Exchange under the symbol "MSI." In August 1999, the Company's Common Stock symbol changed to "ILGN" on the NASDAQ SmallCap Market and "ILG" on the Boston Stock Exchange. Prior to November 1997, there was no established trading market for the Common Stock. The following table sets forth, for the periods indicated, the high and low bid prices for the Common Stock, as reported by the NASDAQ SmallCap Market, since the Common Stock commenced public -17- trading. The quotations represent prices in the over-the-counter market between dealers and securities, and do not include retail markup, markdown or commissions and may not necessarily represent actual transactions. 1999: HIGH LOW ---- --- First Quarter.......................... $1.313 $0.406 Second Quarter ........................ $3.500 $0.781 Third Quarter.......................... $3.313 $1.500 Fourth Quarter......................... $9.000 $1.875 1998: HIGH LOW ---- --- First Quarter.......................... $6.063 $2.938 Second Quarter ........................ $5.00 $3.50 Third Quarter.......................... $4.25 $1.313 Fourth Quarter......................... $2.125 $0.469 1997: HIGH LOW ---- --- November 26 - December 31, 1997 ....... $9.00 $3.875 NUMBER OF SHAREHOLDERS As of March 1, 2000, there were approximately 162 record holders of the Company's Common Stock. DIVIDENDS The Company has not declared any dividends to date and does not plan to declare any dividends in the foreseeable future. SALE OF UNREGISTERED SECURITIES Previously reported. ITEM 6. SELECTED FINANCIAL DATA. The following table sets forth financial data with respect to the Company as of and for each of the five years ended December 31, 1999. The selected financial data as of and for each of the five years ended December 31, 1999 have been derived from the financial statements of the Company. The financial statements and the reports thereon as of December 31, 1999, and 1998 and for the years ended December 31, 1999, 1998 and 1997 are included elsewhere in this Annual Report on Form 10-K. The information below should be read in conjunction with the financial statements (and notes thereon) and Management's Discussion and Analysis of Financial Condition and Results of Operations included in Item 7. -18-
YEARS ENDED DECEMBER 31, -------------------------------------------------------------------------------- 1999 1998 1997 1996 1995 ------------ ------------ ------------ ------------ ------------ Revenues ...................................... $ 477,497 $ 412,942 $ 195,928 $ 1,918,879 $ 1,872,932 Gross Profit .................................. 276,315 196,658 29,486 1,371,113 1,505,412 Expenses: Research and Development ................... 3,570,845 2,799,220 1,223,468 958,249 582,595 Selling, general and administrative ........ 2,904,210 7,220,444 2,868,057 1,162,768 755,785 Operating income (loss) ....................... (6,198,740) (9,803,006) (4,062,039) (749,904) 167,032 Other income (expense): Interest Income ............................ 107,446 379,054 53,889 8,561 35 Interest expense ........................... (59,189) (94,597) (485,062) (34,229) (14,300) Other income (expense) ..................... 11,880 11,124 -- (6,934) -- Net income (loss) ............................. (6,138,603) (9,508,275) (4,494,062) (788,546) 150,012 Net income (loss)applicable to common stock ....................................... (11,138,603) (9,508,275) (4,494,062) (788,546) 150,012 Basic and diluted loss per common share ....... (1.15) (1.72) (1.19) (.18) .03 Weighted-average common shares outstanding ................................. 9,720,621 5,540,895 3,773,474 4,288,436 4,288,436 AS OF DECEMBER 31, -------------------------------------------------------------------------------- 1999 1998 1997 1996 1995 ------------ ------------ ------------ ------------ ------------ Balance Sheet Data: Cash, cash equivalents and marketable securities .................................. $ 2,656,116 $ 2,432,271 $ 12,012,772 55,966 73,000 Working Capital (deficit) ..................... 1,967,943 1,462,748 11,186,863 (735,986) 242,000 Total Assets .................................. 3,176,159 3,672,890 12,823,376 311,962 458,000 Long-term debt and capital lease obligations, less current portion ........... 99,246 604,507 580,739 200,834 -- Shareholders equity ........................... $ 2,153,178 $ 1,846,348 11,286,889 (699,748) 299,000
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS GENERAL OVERVIEW Interleukin Genetics, Inc., a Texas corporation ("ILGN" or the "Company") develops and commercializes genetic diagnostic tests and medical research tools. The Company's efforts are focused on genetic factors that affect the rate of progression of clinical disease through their influence on common host systems. The Company's first genetic test, PST(R), a test predictive of risk for periodontal disease, is currently marketed in the United States, Europe and Israel. Products under development include tests predictive of risk for osteoporosis, coronary artery disease, diabetic retinopathy, asthma, pulmonary fibrosis and meningitis/sepsis. The Company believes by combining genetic risk assessment with specific therapeutic strategies, improved clinical outcomes and more cost-effective management of these common diseases are achieved. ILGN also develops and licenses its medical research tools, including BioFusion(R), to pharmaceutical companies. BioFusion, a proprietary enabling system for diagnostic and drug discovery and development, is a computer modeling system that integrates genetic and other sub-cellular behavior, system functions, and clinical symptoms to simulate complex diseases. This system allows for the utilization of the -19- rapidly increasing databases of gene expression, cell biology, prognostic, pharmacogenomic and predictive medicine databases being generated in companies and academic centers worldwide. The Company has followed a strategy of working with strategic partners at the fundamental discovery stage. This strategy has given the Company access to discoveries while reducing up-front research expenses. Since 1994, the Company has had a strategic alliance with the Department of Molecular and Genetic Medicine at Sheffield University in the United Kingdom ("Sheffield"). Under this alliance, Sheffield has provided to the Company the fundamental discovery and genetic analysis from Sheffield's research laboratories and the Company has focused on product development, including clinical trials, and the commercialization of these discoveries. In October 1999, the Company entered into a new arrangement (the "Agreement") with Sheffield replacing the research and development agreement that had been in place with Sheffield since 1996. Under the Agreement, the Company will undertake the development and commercialization of certain discoveries resulting from Sheffield's research. The Agreement with Sheffield is a five-year agreement with an automatic yearly renewal. Pursuant to this new arrangement, the Company issued an aggregate of 475,000 shares of its Common Stock to Sheffield and its investigators in exchange for the transfer of certain patent rights and the relinquishment of proceeds interests held by Sheffield and its investigators under all project agreements. The Company also entered into a research and development services agreement with Sheffield which automatically renews in one-year increments. In connection with this new arrangement, the Company entered into a five- year consulting agreement with Sheffield's key collaborator. The Company anticipates entering into additional collaborative arrangements with Sheffield and other parties in the future. In December 1997, the Company entered into an agreement with Medicadent, a French corporation ("Medicadent"), to market and sell PST in France. In August 1998, the Company entered into an agreement with H.A. Systems, Ltd. to market and sell PST in Israel. Medicadent commenced offering PST in France in June 1998, and the Company H.A. Systems commenced offering PST in Israel in early 1999. In March 1999, the Company entered into an agreement with the Straumann Company to market and sell PST in the United States and Puerto Rico. Straumann launched its PST promotional activities in April 1999. In April 1999, the Company entered into an agreement with Dumex, a subsidiary of AlPharma, a pharmaceutical manufacturer, to market and sell PST in nine European countries (Austria, Denmark, Finland, Germany, Ireland, Norway, Sweden, Switzerland and the U.K.). Dumex is well known in Europe as a manufacturer of oral health care products used by periodontists. No assurances can be made regarding the commercial acceptance of PST. The Company anticipates additional international agreements for the distribution of PST in 2000, but no assurances can be made that such agreements will be entered into by the Company. The Company has been awarded four U.S. patents, and has sixteen U.S. patent applications pending. The U.S. Patent & Trademark Office awarded patents to the Company for its osteoporosis and periodontal disease susceptibility tests and two patent awards for its biologic modeling technology called BioFusion(R), which is used by the Company in the discovery, development and commercialization process. RESULTS OF OPERATIONS COMPARISON OF YEAR ENDED DECEMBER 31, 1999 TO YEAR ENDED DECEMBER 31, 1998 Revenue for the year ended December 31, 1999 was $477,497 as compared to $412,942 for the year ended December 31, 1998, representing an increase of $64,555 or 16%. The increase in revenue is primarily attributable to higher average selling price per PST test. Cost of revenues was $201,182 for the year ended December 31, 1999 as compared to $216,284 for the same year period in 1998, representing a decrease of $15,102 or 7%. This decrease is primarily attributable to lower laboratory costs for processing PST tests. For the year ended December 31, 1999, the Company had research and development expenses of $3,570,845 as compared to $2,799,220 for 1998, an increase of $771,625 or 28%. This increase was primarily -20- due to $1,128,125 of non-cash expense associated with issuance of 475,000 shares of common stock to the University of Sheffield and its investigators in conjunction with the new arrangement with Sheffield and its investigators entered into in October 1999. Selling, general and administrative expenses decreased for 1999 to $2,904,210 from $7,200,444 in 1998, a decrease of $4,296,234 or 60%. The decrease reflects the reduction in personnel costs as the Company shifted from an internal sales staff to the use of outside distributors to sell its PST tests. Interest income decreased to $107,446 in 1999 from $379,054 in 1998. This decrease is attributable to the reduction in the unused net proceeds of the initial public offering and subsequent private placements as the proceeds are used for ongoing Company operations and a $585,992 reduction in the Company's debt obligations. The reduction in the Company's debt obligations is also the primary reason for the interest expense decreasing from $94,597 in 1998 to $59,189 in 1999, a decrease of $35,408 or 37%. Net losses decreased to $6,138,603 in for the year ended December 31, 1999, as compared to $9,508,275 in 1998, a decrease of $3,369,672 or 35%. Such decreased loss is a result of the decreased expenses set forth above. COMPARISON OF YEAR ENDED DECEMBER 31, 1998 TO YEAR ENDED DECEMBER 31, 1997. Revenue for the year ended December 31, 1998 was $412,942 as compared to $195,928 for the year ended December 31, 1997, representing an increase of $217,014 or 111%. The increase in revenue is primarily attributable to sales of PST, the Company's first genetic test which was made commercially available in the fourth quarter of 1997. Cost of revenues was $216,284 for the year ended December 31, 1998 as compared to $166,442 for the same period in 1997, representing an increase of 30%. This increase is a result of the increase in sales, offset by the Company's ability to take advantage of volume processing discounts provided to it by its outside laboratory vendors. For the year ended December 31, 1998, the Company had research and development expenses of $2,799,220 as compared to $1,223,468 for 1997, an increase of $1,575,752 or 129%. This increase was due to our continued investment in genetic research projects. In addition to the full time employment of key scientists for our coronary artery disease and osteoporosis genetic susceptibility tests, and for new clinical trials which have commenced and are continuing to run for the same two tests, the Company continues to perform science enhancement studies for our PST product, as well as invest in our previously disclosed research projects related to diabetic retinopathy and asthma. One additional factor in the increase of research and development expenses, as discussed above, is the write-down of capitalized patent expenses. The resulting charge, taken in the fourth quarter of 1998, was $886,534, or 32%, of research and development expenses for the year. Management believes it is appropriate to expense these costs after consideration of their current development strategy and available capital. Selling, general and administrative expenses increased for 1998 to $7,200,444 from $2,868,057 for 1997, an increase of $4,332,387 or 151%. This increase is primarily attributable to building the infrastructure required to support commercial operations and the increased marketing and sales efforts required to support the Company's genetic susceptibility testing business. Additionally, general and administrative expenses increased to support the research and development efforts of the Company, and due to increased legal and accounting expenses related to complying with SEC reporting obligations. During the second quarter of 1998, the Company consolidated its corporate headquarters from Newport Beach, California into the Company's San Antonio Research Facility. As a result of this relocation, the Company amended its existing lease in San Antonio to extend the term and expand its premises. The -21- amended lease expires on May 31, 2003 and extends its square footage from approximately 1,961 square feet to 8,131 square feet. Also, as a result of the move from California, the Company has subleased its leased office space in Newport Beach. The sublease expires on the same date of the Company's lease, April 30, 2001. Interest income for the year ended December 31, 1998 increased to $379,054 from $53,889 for 1997. Such increase is attributable entirely to the interest income generated by the unused net proceeds of the initial public offering. Interest expense of $94,597 was incurred during the year ended December 31, 1998, a decrease of 81% from $485,062 over the same period in 1997. Such decrease is attributable to a decrease in the amount of the Company's debt obligations, which were substantially reduced with the net proceeds of the Company's initial public offering. Net losses increased to $9,508,275 for the year ended December 31, 1998, as compared to $4,494,062 for the same period in 1997, an increase of $5,014,213 or 112%. Such increased loss is a result of the increased expenses set forth above. LIQUIDITY AND CAPITAL RESOURCES The Company believes that its cash and cash equivalents are the most significant indicators of the Company's liquidity position. As of December 31, 1999, the Company had cash and cash equivalents of $2,656,116. The cash and cash equivalents position generated interest income of $28,166 in the fourth quarter of 1999, and $107,446 for the year. Net cash used in operating activities was $4,420,167 during the year ended December 31, 1999 as compared to $8,454,858 used during 1998. Marketable securities increased from zero in 1998 to $1,987,500 at December 31, 1999 as the Company purchased U.S. Treasury notes with the unused proceeds from the private placement of $5,000,000 of convertible preferred stock in June 1999. Accounts payable decreased from $278,773 in 1998 to $134,968 in 1999. This decrease was primarily due to the decreased level of operating expenses in late 1999. Additionally, the Company entered into an agreement with a distributor whereby the distributor paid in advance for licensing fees, resulting in Prepaid distributor fees increasing from zero in 1998 to $65,000 in 1999. The current portion of long-term debt decreased from $81,432 in 1998 to zero in 1999 due to the Company's retirement of all outstanding debt in 1999. The Company's investing activities used cash of $1,752,116 in the year ended December 31, 1999 and provided cash of $5,036,678 in 1998. During the year ended December 31, 1999, the Company shifted excess cash from Cash and cash equivalents into Marketable securities to earn a preferred interest rate. Additionally, during 1998, the Company received proceeds from the maturity of investments of $6,226,795 as a result of the maturity of U.S. Treasury bills previously invested in, partially offset by reinvestment in a certificate of deposit. Investing activities were comprised primarily from the maturing of investments and a certificate of deposit and the purchase of investments. Financing activities provided $4,408,628 in 1999 and used $154,608 in 1998. During 1999, the Company received $4,706,927 in net proceeds for the issuance of convertible preferred stock and $380,545 in proceeds for the issuance of common stock, as compared to $5,734 for common stock issued in 1998. In 1999, the Company received proceeds from long term borrowings of $10,688 as compared to $617,813 in 1998. In January of 2000, the Company received $ 4,733,084 in net proceeds from a private placement of 832,667 shares of common stock. The Company currently does not have any commitments for material capital expenditures. The Company's obligation at December 31, 1999 for capitalized lease obligations totaled $163,123, of which $99,246 is classified as long-term and $63,877 is classified as current. -22- The Company anticipates that its existing cash and cash equivalents, together with anticipated interest income and revenue, will be sufficient to conduct its operations as planned until September 2001. However, the Company's future capital requirements are anticipated to be substantial, and the Company does not have commitments for additional capital at this time. Such capital requirements are expected to arise from the commercial launch of additional genetic tests, continued marketing and sales efforts for PST, continued research and development efforts, the protection of the Company's intellectual property rights (including preparing and filing of patent applications), as well as operational, administrative, legal and accounting expenses. The Company plans to raise capital through equity and/or debt issuance when, and if, such capital is available to it. THERE CAN BE NO ASSURANCE THAT THE COMPANY WILL BE ABLE TO RAISE ANY ADDITIONAL NECESSARY CAPITAL. IF ADDITIONAL AMOUNTS CANNOT BE RAISED, THE COMPANY WOULD SUFFER MATERIAL ADVERSE CONSEQUENCES TO ITS BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS AND WOULD LIKELY BE REQUIRED TO SEEK PROTECTION UNDER THE UNITED STATES BANKRUPTCY LAWS. ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK. The Company maintains an investment portfolio consisting of securities of U.S Treasury Notes. The securities held in the Company's investment portfolio are subject to interest rate risk. Changes in interest rates affect the fair market value of these securities. After a review of the Company's marketable securities as of December 31, 1999, the Company has determined that in the event of a hypothetical ten percent increase in interest rates, the resulting decrease in fair market value of the Company's marketable investment securities would be insignificant to the financial statements as a whole. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA The Consolidated Financial Statements of the Company, together with the Independent Auditors Report thereon of each of Arthur Andersen LLP and Singer Lewak Greenbaum & Goldstein LLP, appears on pages F-2 through F-23 of this report. See the "Index to Financial Statements" on page F-1 of this report. ITEM 9. CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE Previously reported. -23- PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT. Information required under this Item will be contained in the Company's Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by reference. ITEM 11. EXECUTIVE COMPENSATION Information required under this Item will be contained in the Company's Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by reference. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT Information required under this Item will be contained in the Company's Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by reference. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS Information required under this Item will be contained in the Company's Proxy Statement for its 2000 Annual Meeting, which is incorporated herein by reference. PART IV ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K. (A) DOCUMENTS FILED AS PART OF REPORT 1. Financial Statements: The Consolidated Financial Statements of the Company and the related report of the Company's independent public accountants thereon have been filed under Item 8 hereof. 2. Financial Statement Schedules: The information required by this item is not applicable. 3. Exhibits: The exhibits listed below are filed as part of or incorporated by reference in this report. Where such filing is incorporated by reference to a previously filed document, such document is identified in parentheses. See the Index of Exhibits included with the Exhibits filed as a part of this report. EXHIBIT NO. IDENTIFICATION OF EXHIBIT 3.1 Articles of Incorporation of the Company, as amended (incorporated herein by reference to the Company's Quarterly Report on Form 10-QSB filed November 15, 1999). -24- 3.2 Amended and Restated Bylaws of the Company, as amended (incorporated herein by reference to Exhibits 3.3 and 3.4 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 4.1 Form of Stock Certificate representing Common Stock, no par value, of the Company (incorporated herein by reference to Exhibit 4.1 of the Company's Registration Statement No. 333-37441 on Amendment No. 1 to Form SB-2 filed October 29, 1997). 4.2 Form of Representative's Warrant (incorporated herein by reference to Exhibit 4.2 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 4.3 Form of Security Agreement (incorporated herein by reference to Exhibit 4.4 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 4.4 Form of Warrant Agreement (incorporated herein by reference to Exhibit 4.5 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 4.5 Form of Warrant Certificate (incorporated herein by reference to Exhibit 4.6 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 4.6 Warrant dated June 15, 1999, granted to Fine Equities, Inc. (incorporated herein by reference to Exhibit 4.2 of the company's Quarterly Report on Form 10-QSB field August 16, 1999). 10.1 Loan Agreement dated June 27, 1997, between the Company and Bank of America (incorporated herein by reference to Exhibit 4.7 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.2+ Research Support Agreement and Amendments to Various Existing Project Agreements dated April 1, 1998, between the Company and The University of Sheffield (incorporated herein by reference to Exhibit 10.2 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.3+ Laboratory Services Agreement dated December 7, 1996, between the Company and Baylor College of Medicine (incorporated herein by reference to Exhibit 10.13 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.4 Lease Agreement dated March 21, 1996, between the Company and Koll Center Newport Number 9 (incorporated herein by reference to Exhibit 10.14 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.5 Lease Agreement dated October 23, 1997, between the Company and Diamond Shamrock Leasing, Inc. (incorporated herein by reference to Exhibit 10.16 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.6 Interleukin Genetics, Inc. 1996 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.17 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.7 Amendment to the Interleukin Genetics, Inc. 1996 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.18 of the Company's Registration Statement No. 333- 37441 on Form SB-2 filed October 8, 1997). -25- 10.8 Form of Stock Option Agreement (incorporated herein by reference to Exhibit 10.19 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.9 Stock Option Exercise Agreement (incorporated herein by reference to Exhibit 10.20 of the Company's Registration Statement No. 333-37441 on Form SB-2 filed October 8, 1997). 10.10+ Exclusive Independent Representative Agreement dated December 1, 1997, between the Company and Medicadent, a French corporation (incorporated herein by reference to Exhibit 10.21 of the Company's Annual Report on Form 10-KSB filed March 31, 1998). 10.11 Consulting and Severance Agreement dated October 28, 1998, between the Company and Michael G. Newman (incorporated herein by reference to Exhibit 10.22 of the Company's Annual Report on Form 10-KSB filed March 31, 1999). 10.12 Amendment to Employment Agreement dated to be effective as of November 17, 1998, between the Company an Paul J. White (incorporated herein by reference to Exhibit 10.23 of the Company's Annual Report on Form 10-KSB filed March 31, 1999). 10.13 Amendment to Employment Agreement dated to be effective as of November 17, 1998, between the Company an Kenneth S. Kornman (incorporated herein by reference to Exhibit 10.24 of the Company's Annual Report on Form 10-KSB filed March 31, 1999). 10.14 Letter Agreement dated January 6, 1997, between the Company and U. Spencer Allen, as amended effective December 1, 1998 (incorporated herein by reference to Exhibit 10.25 of the Company's Annual Report on Form 10-KSB filed March 31, 1999). 10.15 Business Loan Agreement between the Company and Bank of America dated June 5, 1998 (incorporated herein by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-QSB filed May 17, 1999). 10.16+ Distribution Agreement between the Company and The Straumann Company dated March 25, 1999 (incorporated herein by reference to Exhibit 10.2 of the company's Quarterly Report on Form 10-QSB filed May 17, 1999). 10.17 Consulting Services Agreement dated June 1, 1999, between the Company and Philip R. Reilly (incorporated herein by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-QSB filed August 16, 1999). 10.18 Non-Qualified Stock Option Agreement dated June 1, 1999, between the Company and Philip R. Reilly (incorporated herein by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-QSB filed August 16, 1999). 10.19 Form of Subscription Agreement (incorporated herein by reference to Exhibit 10.3 of the Company's Quarterly Report on Form 10-QSB filed August 16, 1999). 10.20 Agency Agreement dated June 15, 1999, between the Company and Fine Equities, Inc. (incorporated herein by reference to Exhibit 10.4 of the Company's Quarterly Report on Form 10-QSB filed August 16, 1999). -26- 10.21+ Research and Technology Transfer Agreement dated effective July 1, 1999, between the Company and the University of Sheffield (incorporated herein by reference to Exhibit 10.1 of the Company's Quarterly Report on Form 10-QSB filed November 15, 1999). 10.22+ Research Support Agreement dated effective July 1, 1999, between the Company and the University of Sheffield (incorporated herein by reference to Exhibit 10.2 of the Company's Quarterly Report on Form 10-QSB filed November 15, 1999). 10.23+ Consulting Agreement dated effective July 1, 1999, between the Company and Gordon Duff, PhD, FRCP (incorporated herein by reference to Exhibit 10.3 of the Company's Quarterly Report on Form 10-QSB filed November 15, 1999). 10.24 Non-Qualified Stock Option Agreement dated November 30, 1999 between the Company and Philip R. Reilly (incorporated herein by reference to Exhibit 4.5 to the Company's Registration Statement No. 333-32538 on Form S-8 filed March 15, 2000). 10.25* Employment Agreement dated December 1, 1999 between the Company and Kenneth S. Kornman. 10.26* Employment Agreement dated April 1, 2000 between the Company and Philip R. Reilly. 10.27* Severance Agreement dated September 20, 1999 between the Company and Paul White. 16.1 Letter from Singer Lewak Greenbaum & Goldstein LLP dated October 26, 1998, to the Securities and Exchange Commission pursuant to Item 304(a)(3) of Regulation S-K (incorporated herein by reference to Exhibit 16 of the Company's current report on Form 8-K filed November 2, 1998). 21.1 Subsidiaries of the Company
NAMES UNDER WHICH NAME INCORPORATED SUBSIDIARY DOES BUSINESS - ----------------------------------------------------- ---------------------------- ------------------------ Medical Science Systems France E.U. France N/A Interleukin Genetics Laboratory Services, Inc. Delaware N/A Interleukin Genetics, Inc. Delaware N/A
23.1* Consent of Arthur Andersen LLP 23.2* Consent of Singer Lewak Greenbaum & Goldstein LLP 27.* Financial Data Schedule. - ----------------- * Filed herewith. + Confidential treatment has been requested with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission. (b) REPORTS ON FORM 8-K -27- The Company filed a report on Form 8-K October 8, 1999 to report a new contractual arrangement with the University of Sheffield. The Company filed a report on Form 8-K December 17, 1999 to report the deadline for shareholder proposals for the annual meeting. -28- In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this amended report to be signed on its behalf by the undersigned, thereunto duly authorized. INTERLEUKIN GENETICS, INC. Date: April 12, 2000 By: U. SPENCER ALLEN U. Spencer Allen Chief Financial Officer, Secretary and Treasurer In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
SIGNATURES TITLE DATE SIGNED ---------- ----- ----------- /s/ PHILIP R. REILLY Chairman of the Board of Directors April 12, 2000 Philip R. Reilly and Chief Executive Officer /s/ KENNETH S. KORNMAN President and Director April 12, 2000 Kenneth S. Kornman /s/ U. SPENCER ALLEN Chief Financial Officer, Secretary and Treasurer April 12, 2000 U. Spencer Allen (PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER) /s/ THOMAS A. MOORE Director April 12, 2000 Thomas A. Moore /s/ EDWARD M. BLAIR, JR. Director April 12, 2000 Edward M. Blair, Jr. /s/ GARY L. CROCKER Director April 12, 2000 Gary L. Crocker
-29- INTERLEUKIN GENETICS, INC. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 1999, 1998 AND 1997 TOGETHER WITH AUDITORS' REPORT INTERLEUKIN GENETICS, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS - -------------------------------------------------------------------------------- Page REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS F-2 REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS F-3 CONSOLIDATED FINANCIAL STATEMENTS: Consolidated Balance Sheets - December 31, 1999 and 1998 F-4 Consolidated Statements of Operations - For the Years Ended December 31, 1999, 1998 and 1997 F-6 Consolidated Statements of Shareholders' Equity - For the Years Ended December 31, 1999, 1998 and 1997 F-7 Consolidated Statements of Cash Flows - For the Years Ended December 31, 1999, 1998 and 1997 F-8 Notes to Consolidated Financial Statements F-10 F-1 REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS To Interleukin Genetics, Inc.: We have audited the accompanying consolidated balance sheets of Interleukin Genetics, Inc. (a Texas corporation), as of December 31, 1999 and 1998, and the related consolidated statements of operations, shareholders' equity and comprehensive income and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Interleukin Genetics, Inc., as of December 31, 1999 and 1998, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States. /s/ ARTHUR ANDERSEN LLP San Antonio, Texas March 29, 2000 F-2 REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS To the Board of Directors and Shareholders Medical Science Systems, Inc. We have audited the consolidated statements of operations, shareholders' equity, and cash flows of Medical Science Systems, Inc. and subsidiary as of December 31, 1997. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated results of Medical Science Systems, Inc. and subsidiary's operations and their consolidated cash flows for the year ended December 31, 1997 in conformity with generally accepted accounting principles. SINGER LEWAK GREENBAUM & GOLDSTEIN LLP Los Angeles, California March 13, 1998 F-3 INTERLEUKIN GENETICS, INC. CONSOLIDATED BALANCE SHEETS DECEMBER 31, 1999 AND 1998 - -------------------------------------------------------------------------------- ASSETS 1999 1998 ---------- ---------- CURRENT ASSETS: Cash and cash equivalents ..................... $ 668,616 $2,432,271 Marketable securities ......................... 1,987,500 -- Accounts receivable, net of allowance for doubtful accounts of $55,300 in 1999 and $20,959 in 1998 ............................. 103,002 125,086 Prepaid expenses .............................. 132,560 127,426 ---------- ---------- Total current assets ............. 2,891,678 2,684,783 FURNITURE AND EQUIPMENT, net ..................... 284,481 458,107 OTHER ASSETS ..................................... -- 530,000 ---------- ---------- TOTAL ASSETS ..................... $3,176,159 $3,672,890 ========== ========== The accompanying notes are an integral part of these consolidated financial statements. F-4 INTERLEUKIN GENETICS, INC. CONSOLIDATED BALANCE SHEETS (CONTINUED) DECEMBER 31, 1999 AND 1998 - -------------------------------------------------------------------------------- LIABILITIES AND SHAREHOLDERS' EQUITY 1999 1998 ------------ ------------ CURRENT LIABILITIES: Accounts payable ............................. $ 134,968 $ 278,773 Accrued expenses ............................. 400,281 433,859 Notes payable ................................ 1,797 47,813 Deferred revenue ............................. 322,812 275,321 Current portion of long-term debt ............ -- 81,432 Current portion of capitalized lease obligations ................................ 63,877 104,837 ------------ ------------ Total current liabilities ................. 923,735 1,222,035 LONG-TERM DEBT, less current portion ............ -- 447,856 CAPITALIZED LEASE OBLIGATIONS, less current portion ....................................... 99,246 156,651 ------------ ------------ Total liabilities ......................... 1,022,981 1,826,542 ------------ ------------ COMMITMENTS AND CONTINGENCIES (Note 9) SHAREHOLDERS' EQUITY: Preferred stock, no par value 5,000,000 shares authorized none issued and outstanding .... -- -- Common stock, no par value 50,000,000 shares authorized in 1999 and 10,000,000 shares authorized in 1998, 17,223,302 and 5,548,470 shares issued and outstanding in 1999 and 1998, respectively ............... 23,177,865 16,719,933 Accumulated deficit .......................... (21,012,188) (14,873,585) Other comprehensive loss ..................... (12,499) -- ------------ ------------ Total shareholders' equity ................ 2,153,178 1,846,348 ------------ ------------ TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 3,176,159 $ 3,672,890 ============ ============ The accompanying notes are an integral part of these consolidated financial statements. F-5 INTERLEUKIN GENETICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997 - --------------------------------------------------------------------------------
1999 1998 1997 ------------ ------------ ------------ REVENUE .................................. $ 477,497 $ 412,942 $ 195,928 COST OF REVENUE .......................... 201,182 216,284 166,442 ------------ ------------ ------------ GROSS PROFIT ............................. 276,315 196,658 29,486 ------------ ------------ ------------ EXPENSES: Research and development .............. 3,570,845 2,799,220 1,223,468 Selling, general, and administrative .. 2,904,210 7,200,444 2,868,057 ------------ ------------ ------------ Total expenses ..................... 6,475,055 9,999,664 4,091,525 ------------ ------------ ------------ LOSS FROM OPERATIONS ..................... (6,198,740) (9,803,006) (4,062,039) ------------ ------------ ------------ OTHER INCOME (EXPENSE): Interest income ....................... 107,446 379,054 53,889 Interest expense ...................... (59,189) (94,597) (485,062) Other income .......................... 11,880 11,124 -- ------------ ------------ ------------ Total other income (expense) ....... 60,137 295,581 (431,173) ------------ ------------ ------------ LOSS BEFORE PROVISION FOR INCOME TAXES ... (6,138,603) (9,507,425) (4,493,212) PROVISION FOR INCOME TAXES ............... -- 850 850 ------------ ------------ ------------ NET LOSS ................................. $ (6,138,603) $ (9,508,275) $ (4,494,062) ============ ============ ============ RECONCILIATION OF NET LOSS TO NET LOSS APPLICABLE TO COMMON STOCK: Net loss .............................. $ (6,138,603) $ (9,508,275) $ (4,494,062) Amortization of the value of the beneficial conversion feature of the preferred stock ..................... 5,000,000 -- -- ------------ ------------ ------------ NET LOSS APPLICABLE TO COMMON STOCK ...... $(11,138,603) $ (9,508,275) $ (4,494,062) ============ ============ ============ BASIC AND DILUTED LOSS PER COMMON SHARE .. $ (1.15) $ (1.72) $ (1.19) ============ ============ ============ WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING 9,720,621 5,540,895 3,773,474 ============ ============ ============
The accompanying notes are an integral part of these consolidated financial statements. F-6 INTERLEUKIN GENETICS, INC. CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997 - --------------------------------------------------------------------------------
COMMON STOCK PREFERRED STOCK ----------------------------- ----------------------------- SHARES AMOUNT SHARES AMOUNT ------------ ------------ ------------ ------------ BALANCE, DECEMBER 31, 1996 .......... 3,295,539 $ 171,500 -- $ -- Net loss ............................ -- -- -- -- Common stock issued: Private placements .............. 442,468 2,019,100 -- -- Initial public offering ......... 1,800,000 16,200,000 -- -- Offering costs ...................... -- (2,540,078) -- -- Stock options issued for reduction in salary .......................... -- 445,132 -- -- Issuance of warrants resulting in additional interest expense ..................... -- 356,545 -- -- Exercise of stock options ........... 8,939 42,356 -- -- Repurchase of common stock .......... (6,051) (42,356) -- -- ------------ ------------ ------------ ------------ BALANCE, DECEMBER 31, 1997 .......... 5,540,895 16,652,199 -- -- Net loss ............................ -- -- -- -- Common stock issued: Employee stock purchase plan ............... 7,575 5,734 -- -- Stock options issued: For services rendered ........... -- 62,000 -- -- ------------ ------------ ------------ ------------ BALANCE, DECEMBER 31, 1998 .......... 5,548,470 16,719,933 -- -- Net loss ............................ -- -- -- -- Unrealized loss on securities ....... -- -- -- -- Comprehensive Loss .................. -- -- -- -- Preferred stock issued: Private placement ............... -- -- 2,200,000 4,706,927 Common stock issued: Preferred stock conversion ...... 11,000,000 4,706,927 (2,200,000) (4,706,927) For services rendered ........... 475,000 1,128,125 -- -- Exercise of stock options ....... 199,314 379,945 -- -- Employee stock purchase plan ............... 518 600 -- -- Stock options issued: For services rendered ........... -- 242,335 -- -- ------------ ------------ ------------ ------------ BALANCE, DECEMBER 31, 1999 .......... 17,223,302 $ 23,177,865 -- $ -- ============ ============ ============ ============ OTHER ACCUMULATED COMPREHENSIVE DEFICIT LOSS TOTAL ------------ ------------ ------------ BALANCE, DECEMBER 31, 1996 .......... $ (871,248) $ -- $ (699,748) Net loss ............................ (4,494,062) -- (4,494,062) Common stock issued: Private placements .............. -- -- 2,019,100 Initial public offering ......... -- -- 16,200,000 Offering costs ...................... -- -- (2,540,078) Stock options issued for reduction in salary .......................... -- -- 445,132 Issuance of warrants resulting in additional interest expense ..................... -- -- 356,545 Exercise of stock options ........... -- -- 42,356 Repurchase of common stock .......... -- -- (42,356) ------------ ------------ ------------ BALANCE, DECEMBER 31, 1997 .......... (5,365,310) -- 11,286,889 Net loss ............................ (9,508,275) -- (9,508,275) Common stock issued: Employee stock purchase plan ............... -- -- 5,734 Stock options issued: For services rendered ........... -- -- 62,000 ------------ ------------ ------------ BALANCE, DECEMBER 31, 1998 .......... (14,873,585) -- 1,846,348 Net loss ............................ (6,138,603) -- (6,138,603) Unrealized loss on securities ....... -- (12,499) (12,499) ------------ Comprehensive Loss .................. -- -- (6,151,102) Preferred stock issued: Private placement ............... -- -- 4,706,927 Common stock issued: Preferred stock conversion ...... -- -- -- For services rendered ........... -- -- 1,128,125 Exercise of stock options ....... -- -- 379,945 Employee stock purchase plan ............... -- -- 600 Stock options issued: For services rendered ........... -- -- 242,335 ------------ ------------ ------------ BALANCE, DECEMBER 31, 1999 .......... $(21,012,188) $ (12,499) $ 2,153,178 ============ ============ ============
The accompanying notes are an integral part of these consolidated financial statements. F-7 INTERLEUKIN GENETICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997 - --------------------------------------------------------------------------------
1999 1998 1997 ----------- ----------- ----------- CASH FLOWS FROM OPERATING ACTIVITIES: Net loss .......................................... $(6,138,603) $(9,508,275) $(4,494,062) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization .................. 194,611 178,283 74,368 Amortization (accretion) of investment premium and discount ....................... 24,375 (219,082) (7,102) Issuance of stock options for reduction of salary .................................. -- -- 445,132 Issuance of stock options for services rendered ................................... 242,335 62,000 -- Issuance of stock for services rendered ........ 1,128,125 -- -- Issuance of warrants resulting in additional interest expense ................ -- -- 356,545 Write down of patents .......................... 241,932 886,534 -- Other noncash expenses ......................... -- 31,272 -- (Increase) decrease in: Accounts receivable, net ................... 22,084 (87,971) (24,756) Inventories ................................ -- 50,212 (50,212) Prepaid expenses ........................... (5,134) (84,914) (42,512) Due from shareholder ....................... -- -- 6,565 Increase (decrease) in: Accounts payable ........................... (143,805) (271,414) 330,518 Accrued expenses ........................... (33,578) 306,177 70,595 Accrued officer compensation ............... -- -- (127,500) Deferred revenue ........................... 47,491 202,320 73,001 ----------- ----------- ----------- Net cash used in operating activities ............. (4,420,167) (8,454,858) (3,389,420) ----------- ----------- ----------- CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of furniture and equipment .............. (15,810) (216,597) (60,504) Increase in patents .............................. (241,932) (443,520) (307,710) Purchase of investments .......................... (4,024,374) -- (6,000,611) Proceeds from maturity of investments ............ 2,000,000 6,226,795 -- Proceeds from (investment in) certificate of deposit ..................................... 530,000 (530,000) -- ----------- ----------- ----------- Net cash provided by (used in) investing activities (1,752,116) 5,036,678 (6,368,825) ----------- ----------- -----------
The accompanying notes are an integral part of these consolidated financial statements. F-8 INTERLEUKIN GENETICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED) FOR THE YEARS ENDED DECEMBER 31, 1999, 1998, AND 1997 - --------------------------------------------------------------------------------
1999 1998 1997 ------------ ------------ ------------ CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of common stock ................ $ 380,545 $ 5,734 $ 18,219,100 Proceeds from sale of convertible preferred stock . 5,000,000 -- -- Payment of offering costs ......................... (293,073) -- (2,540,078) Proceeds from note payable and long-term debt ..... 10,688 617,813 -- Principal payments on notes payable and long-term debt ............................... (585,992) (673,012) (85,987) Borrowings on line of credit, net ................. -- -- 146,277 Principal payments on capital lease obligations ... (103,540) (105,143) (31,974) Proceeds from promissory notes .................... -- -- 1,780,000 Principal payments on promissory notes ............ -- -- (1,780,000) ------------ ------------ ------------ Net cash provided by (used in) financing activities 4,408,628 (154,608) 15,707,338 ------------ ------------ ------------ Net increase (decrease) in cash and cash equivalents ...................................... (1,763,655) (3,572,788) 5,949,093 CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD ...... 2,432,271 6,005,059 55,966 ------------ ------------ ------------ CASH AND CASH EQUIVALENTS, END OF PERIOD ............ $ 668,616 $ 2,432,271 $ 6,005,059 ============ ============ ============ SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Interest paid .................................... $ 59,189 $ 94,597 $ 126,149 ============ ============ ============ Income taxes paid ................................ $ -- $ 1,660 $ 800 ============ ============ ============
SUPPLEMENTAL SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES: During the years ended December 31, 1999, 1998 and 1997, the Company acquired furniture and equipment of $5,175, $182,042 and $149,847, respectively, under capitalized lease obligations. During the year ended December 31, 1997, the Company converted its line of credit for $500,000 into a note payable for $500,000. In addition, in a noncash exchange, a shareholder exchanged 6,051 shares of the Company's common stock as consideration for the exercise price of 8,939 stock options, which resulted in a net issuance of 2,888 shares of common stock to this shareholder. During the year ended December 31, 1999, the Company had other comprehensive loss of $12,499, which represents an unrealized loss on marketable securities. The accompanying notes are an integral part of these consolidated financial statements. F-9 INTERLEUKIN GENETICS, INC. NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 1999, 1998 AND 1997 NOTE 1 - COMPANY BACKGROUND AND UNCERTAINTIES ORGANIZATION AND LINE OF BUSINESS In August 1999, Medical Science Systems, Inc, was renamed Interleukin Genetics, Inc. (the Company). The Company is currently developing genetic diagnostic tests and medical research tools. As of December 31, 1999, the Company has commercially introduced one such product and is in various stages of development for several others. Additionally, the Company provides research services under contract to pharmaceutical companies. Such research services contributed less than 10% of net revenue to the Company in 1999, 1998 and 1997. The accompanying financial statements of the Company have been prepared on the basis of accounting principles applicable to a going concern. Since its inception, the Company has incurred cumulative net losses of approximately $21.0 million, including losses of approximately $6.1 million during 1999, $9.5 million during 1998 and $4.5 million during 1997. For the years ended December 31, 1999, 1998 and 1997, the Company reported negative cash flows from operating activities of approximately $4.4 million, $8.5 million and $3.4 million, respectively. As a result of these losses, available cash resources have been limited. While the Company continues to pursue sources of capital, there can be no assurance that they will be successful in these efforts. During 1999, the Company raised approximately $5.1 million from a preferred stock offering and shareholder stock option exercises. Additionally, in January 2000, the Company completed a common stock private placement which raised net proceeds of approximately $4.7 million. (See Notes 7 and 12.) The Company believes that their current cash resources are more than adequate to fund operations throughout the year 2000, however, absent additional equity or debt financings, they also believe that those resources will be depleted in September 2001. To address these future capital resources requirements, management of the Company is currently in discussions with several potential strategic partners regarding the up-front funding of certain of the Company's research and development programs. Commercial success of genetic susceptibility tests will depend upon their acceptance as medically useful and cost-effective by patients, physicians, dentists, other members of the medical and dental community, and third-party payers. It is uncertain whether current genetic susceptibility tests or others that the Company may develop will gain commercial acceptance on a timely basis. F-10 Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad which have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop susceptibility tests and launch such services or products before their competitors, then revenues may be reduced or eliminated. The Company's ability to successfully commercialize genetic susceptibility tests depends on obtaining adequate reimbursement for such products and related treatment from government and private health care insurers and other third-party payers. Doctors' decisions to recommend genetic susceptibility tests will be influenced by the scope and reimbursement for such tests by third-party payers. If both third-party payers and individuals are unwilling to pay for the test, then the number of tests performed will significantly decrease, therefore resulting in a reduction of revenues. In July 1999, the Company entered into an agreement with Sheffield University, whereby the Company will undertake the development and commercialization of certain discoveries resulting from Sheffield University's research. The agreement is non cancelable for discoveries on which the parties have reached a specific agreement, but may be terminated with or without cause by either party upon six-months notice with respect to new discoveries on which the parties have not yet reached agreement. If Sheffield University terminated the agreement, such termination could make the discovery and commercial introduction of new products more difficult or unlikely. NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated. ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reported periods. Actual results could differ from those estimates. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company measures its financial assets and liabilities in accordance with generally accepted accounting principles. For certain of the Company's financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, the carrying amounts approximate fair value due to their short maturities. The amounts shown for long-term debt, notes payable and capital lease obligations also approximate fair value because current interest rates and terms offered to the Company for similar debt and lease agreements are substantially the same. F-11 CASH AND CASH EQUIVALENTS For purposes of the statements of cash flows, the Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company maintains cash deposits at primarily one bank. Deposits at this bank are insured by the Federal Deposit Insurance Corporation up to $100,000. As of December 31, 1999, uninsured portions of balances held at this financial institution totaled $522,765. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and cash equivalents. MARKETABLE SECURITIES Marketable securities are classified as available for sale and recorded at current market value. Unrealized losses on such securities are reflected as other comprehensive loss in shareholders' equity. FURNITURE AND EQUIPMENT Furniture and equipment, including equipment under capital leases, are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of three to five years. Leasehold improvements are amortized over the life of the lease or the life of the improvement, whichever is shorter. (See Note 4.) Betterments, renewals, and extraordinary repairs that extend the life of the asset are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the statement of operations. In 1999, the Company wrote-off $25,893 of leasehold improvements related to a lease for office space. A portion of this office space was subleased in 1999. PATENTS The Company expensed $241,932 in 1999 and $886,534 in 1998 of patent costs incurred for existing products or those which may be developed in the future. Management believes it is appropriate to expense these costs after consideration of their current development strategy and available capital. DISTRIBUTOR FEES The Company has entered into multiple agreements for the distribution of genetic susceptibility tests, both domestically and internationally. Distributor fees are received based on the terms of each agreement and are recognized ratably over the applicable agreement period. Distributor fees received in advance totaled $65,000 at December 31, 1999, and are included in deferred revenue in the accompanying consolidated balance sheets. F-12 REVENUE RECOGNITION Revenue from genetic susceptibility tests is recognized when the tests have been completed and the results reported to the doctors. To the extent test kits have been purchased but not yet submitted for test results, the Company defers recognition of revenue. This amount is presented as deferred revenue in the accompanying balance sheets. Contract revenues are recognized ratably as services are provided based on a fixed contract price or on negotiated hourly rates. Provision for anticipated losses on fixed-price contracts is made in the period such losses are identified. RESEARCH AND DEVELOPMENT Research and development costs related to the development of new products are expensed as incurred. INCOME TAXES The Company files a consolidated U.S. Federal income tax return which includes all of its U.S. subsidiaries and a separate French federal income tax return for the French subsidiary. Deferred income taxes are provided when certain revenues and expenses are reported in periods which are different for financial reporting purposes than for income tax reporting purposes. Deferred tax liabilities and assets are recorded based on the enacted income tax rates which are expected to be in effect in the periods in which the deferred tax liability or asset is expected to be settled or realized. A change in the tax laws or rates results in adjustments to the deferred tax liabilities and assets. The effect of such adjustments is included in income in the period in which the tax laws or rates are changed. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. NET LOSS PER SHARE The Company applies Statement of Financial Accounting Standards No. 128, "Earnings per Share" ("SFAS 128"), in calculating basic and diluted loss per share. Basic loss per share is determined by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted loss per share is determined by dividing net loss by the weighted average number of shares of common stock and potential common stock outstanding during the period. Stock options with an exercise price below fair market value for any of the periods presented are considered potential common stock. Various stock options granted to vendors and employees in connection with the Company's stock compensation plans were outstanding during the years ended December 31, 1999 and 1998, but were not included in the computation of diluted loss per share for such periods because the effect would have been antidilutive. Options to purchase approximately 1.7 million shares of common stock were outstanding at December 31, 1999. F-13 NOTE 3 - ACCOUNTS RECEIVABLE The changes in the allowance for doubtful accounts consisted of the following: DECEMBER 31 ------------------------ 1999 1998 -------- -------- Beginning of year .............................. $ 20,959 $ 1,000 Provision charged to expense ................... 48,000 20,000 Accounts written off, net of recoveries ........ (13,659) (41) -------- -------- End of year .................................... $ 55,300 $ 20,959 ======== ======== NOTE 4 - FURNITURE AND EQUIPMENT Furniture and equipment useful lives and balances at December 31, 1999 and 1998, consisted of the following: 1999 1998 -------------- ------------ Computer equipment 3 years $ 299,004 $ 289,772 Lab equipment 5 years 6,578 - Furniture and fixtures 5 years 32,304 32,304 Office equipment 3 years 37,769 37,769 Leasehold improvements 5 years 60,310 60,310 Equipment under capitalized leases 3 to 5 years 377,627 372,452 -------------- ------------ 813,592 792,607 Less- Accumulated depreciation and amortization 529,111 334,500 -------------- ------------ TOTAL $ 284,481 $ 458,107 ============== ============ NOTE 5 - NOTES PAYABLE AND LONG-TERM DEBT In May 1998, outstanding notes payable were combined into a single-term loan which matured in June 2005. The Company had provided a $530,000 certificate of deposit as security for this note. The principal balance of $570,000 was due in monthly installments of $6,786, plus interest. In June 1999, the Company used the proceeds from the certificate of deposit to repay the remaining principal balance. NOTE 6 - INCOME TAXES As of December 31, 1999, the Company had net operating loss (NOL) and research tax credit carryforwards of approximately $18,750,000 and $187,000, respectively, for federal income tax purposes, expiring in varying amounts through the year 2019. The Company's ability to use its NOL and credit carryforwards to reduce future taxes is subject to the restrictions provided by Section 382 of the Internal Revenue Code of 1986 (the "Code"). F-14 These restrictions provide for limitations on the Company's utilization of its NOL and credit carryforwards following a greater than 50% ownership change during the prescribed testing period. As of December 31, 1999, the Company had incurred such a change. As a result, approximately $15,619,000 of the Company's NOL carryforwards are limited in utilization to approximately $825,000 annually. The annual limitation may result in the expiration of the carryforwards prior to utilization. As of December 31, 1999 and 1998, deferred tax assets (liabilities) consisted of the following: 1999 1998 ----------- ----------- Deferred tax assets: Net operating loss carryforwards .......... $ 6,374,221 $ 4,432,995 Research tax credit carryforwards ......... 187,395 170,129 Accrual to cash adjustments ............... 211,650 242,924 Charitable contributions .................. -- 7,293 Stock options ............................. 90,092 -- Depreciation .............................. 22,496 -- Patents ................................... 60,856 83,265 ----------- ----------- Total deferred tax assets ............. 6,946,710 4,936,606 Deferred tax liabilities: Depreciation and amortization ............. -- (11,216) ----------- ----------- 6,946,710 4,925,390 Valuation allowance for net deferred tax assets ............................... 6,946,710 4,925,390 ----------- ----------- NET DEFERRED TAX ASSETS ................... $ -- $ -- =========== =========== As there is no assurance of future income, a 100% valuation reserve has been established against the Company's deferred tax assets. NOTE 7 - CAPITAL STOCK PRIVATE PLACEMENT OF PREFERRED STOCK Pursuant to a private placement which occurred in June 1999, the Company issued 2,200,000 shares of its Series A Preferred Stock, no par value (Series A Stock), for $5 million. In conjunction with this offering, the placement agent received 200,000 shares of Series A Stock and a warrant to purchase 1,000,000 shares of common stock at a price of $0.50 per share. This warrant expires on June 16, 2004. Each share of the Series A Stock was automatically converted into five shares of the Company's common stock at a conversion price of $0.50 per share upon the approval of the private placement by the Company's shareholders on August 20, 1999. The Company filed a Registration Statement registering the resale of the shares of the common stock underlying the Series A Stock on July 23, 1999, which was declared effective by the SEC on September 14, 1999. On the closing date of the private placement, the conversion price of the Series A Stock was less than the market price of the common stock, which resulted in a beneficial conversion of $5 million. The beneficial conversion was recorded as common stock and was accreted to preferred stock ratably from the closing date of the preferred stock to August 20, 1999. F-15 EMPLOYEE STOCK PURCHASE PLAN Effective October 14, 1998, the Company's Board of Directors approved an Employee Stock Purchase Plan for qualified employees of the Company. Under the terms of the Employee Stock Purchase Plan, an employee may purchase up to $25,000 per calendar year of the Company's stock at a price of 85% of the fair market value of the stock (as quoted on the NASDAQ national quotation system) on the date of the purchase. The purchase price is determined based upon either the first or last day of a calendar quarter. There have been 500,000 shares of the Company's stock set aside for purchases to be made under the Employee Stock Purchase Plan. During the years ended December 31, 1999 and 1998, 518 and 7,575 shares were purchased under the Employee Stock Purchase Plan at a price of approximately $1.159 and $0.757, respectively, per share. NOTE 8 - EMPLOYEE BENEFIT PLAN In 1988, the Company adopted a profit sharing plan covering substantially all of its employees. Under the profit sharing plan, the Company may, at the discretion of the Board of Directors, contribute a portion of the Company's current or accumulated earnings. In September 1998, the Company amended and restated the profit sharing plan to include provisions for Section 401(k) of the Internal Revenue Code. Under the amended and restated plan, the Company may, at the discretion of the Board of Directors, "match" a portion of the participant contributions. Company contributions, if any, are credited to the participant's account and vest over a period of four years based on the participant's initial service date with the Company. During the years ended December 31, 1999, 1998, and 1997, no contributions were made to the amended and restated profit sharing plan or the original profit sharing plan, respectively. NOTE 9 - STOCK OPTION PLAN The Company applies SFAS No. 123, "Accounting for Stock-Based Compensation" (SFAS 123), which defines a fair value based method of accounting for employee stock options or similar equity instruments and encourages all entities to adopt that method of accounting for all of their employee stock compensation plans. Under the fair value based method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period of the award, which is usually the vesting period. However, SFAS 123 also allows entities to continue to measure compensation costs for employee stock compensation plans using the intrinsic value method of accounting prescribed in APB Opinion No. 25, "Accounting for Stock Issued to Employees" (APB 25). The Company has elected to remain with the accounting prescribed by APB 25. The Company has made the required disclosures prescribed by SFAS 123. In June 1996, the Company's shareholders approved the adoption of the Medical Science Systems, Inc. 1996 Equity Incentive Plan (the "Plan"). The Plan provides for the award of nonqualified and incentive stock options, restricted stock, and stock bonuses to employees, directors, officers, and consultants of the Company. A total of 1,300,000 shares of the Company's common stock have been reserved for award under the amended Plan. Nonqualified and incentive stock options with a life of ten years are granted at exercise prices equal to the fair market value of the common stock on the date of grant. Options granted before December 31, 1997, vest as follows: one-sixth of the options are generally available for exercise F-16 at the end of six months and the remainder of the grant is exercisable ratably over the next 30-month period provided the optionee remains in service to the Company. Options granted after January 1, 1998, vest ratably over four years after each anniversary date provided the optionee remains in service to the Company. The Company may also award share appreciation rights ("SARs") either in tandem with stock options or independently. At December 31, 1999, 1998, and 1997, no SARs have been awarded under the Plan. On October 14, 1998, the Company's Board of Directors voted to reduce the exercise price for all outstanding options granted under the 1996 Equity Incentive Plan to one half of the previous price per share, but not to a price below $1.85 per share. The close of the Company's common stock on the previous day was $1.25 per share. Had compensation cost for these options been determined consistent with SFAS 123, the Company's net loss and net loss per share (EPS) would have been changed to the following pro forma amounts at December 31:
1999 1998 1997 -------------- -------------- -------------- Net loss applicable to common stock ............. As Reported $ (11,138,603) $ (9,508,275) $ (4,494,062) Pro Forma (12,024,156) (9,855,915) (4,796,791) EPS ........................ As Reported $ (1.15) $ (1.72) $ (1.19) Pro Forma (1.24) (1.78) (1.27)
The fair value of each option grant is estimated on the date of grant using an option pricing model, which approximates the Black-Scholes option pricing model, for a stock that does not pay dividends with the following assumptions. YEARS ENDED DECEMBER 31, ------------------------------------- 1999 1998 1997 --------- --------- --------- Risk free interest rate .............. 4.7%-6.2% 5.5% 6.4% Expected life ........................ 7 years 7 years 7 years Expected volatility .................. 156% 143% 61% Because the SFAS 123 method of accounting has not been applied to options granted prior to January 1, 1995, the resulting pro forma compensation cost may not be representative of that to be expected in future years. F-17 A summary of the status of the Company's stock options, issued both under the Plan and outside the Plan, at December 31, 1999, 1998 and 1997, and changes during the years then ended is presented in the table and narrative below:
1999 1998 1997 --------------------------- --------------------------- --------------------------- WEIGHTED WEIGHTED WEIGHTED AVERAGE AVERAGE AVERAGE EXERCISE EXERCISE EXERCISE PRICE PRICE PRICE SHARES PER SHARE SHARES PER SHARE SHARES PER SHARE ----------- ----------- ----------- ----------- ----------- ----------- Outstanding, beginning of year 1,174,383 $ 2.20 792,640 $ 4.37 142,500 $ 3.70 Granted ....... 1,061,781 $ 2.05 1,188,783 $ 2.31 659,079 $ 4.46 Exercised ..... (199,314) $ 1.98 -- -- (8,939) $ 4.74 Canceled ...... (314,720) $ 2.15 (807,040) $ 4.37 -- -- ----------- ----------- ----------- Outstanding, end of year ..... 1,722,130 $ 2.11 1,174,383 $ 2.20 792,640 $ 4.37 Options exercisable, end of year ......... 889,852 487,502 212,543 Weighted average fair value of options granted . $ 2.48 $ 1.39 $ 2.55
The following table summarizes the information about options outstanding at December 31, 1999: STOCK OPTIONS OUTSTANDING STOCK OPTIONS EXERCISABLE ----------------------------------- ------------------------- WEIGHTED AVERAGE NUMBER REMAINING WEIGHTED EXERCISABLE WEIGHTED CONTRACTUAL AVERAGE AT AVERAGE RANGE OF NUMBER LIFE EXERCISE DECEMBER 31, EXERCISE EXERCISE PRICES OUTSTANDING (YEARS) PRICE 1999 PRICE - --------------- ----------- ------- --------- ---------- --------- $.50 - $.99 344,265 9.37 $ .58 132,568 $ .65 $1.00 - $1.49 64,350 8.92 1.25 64,350 1.25 $1.50 - $1.99 286,814 7.34 1.82 274,119 1.82 $2.00 - $2.49 182,800 8.69 2.25 136,767 2.28 $2.50 - $6.00 843,901 9.22 2.86 282,048 2.83 ---------- ---------- 1,722,130 $ 2.11 889,852 $1.99 ========== ========== The Plan also provides for the award of restricted stock to eligible persons. Such awards may be at prices not less than 85% of the fair market value of the Company's common stock as determined by the Board of Directors. In addition, stock bonuses may be awarded to certain employees or officers of the Company at the discretion of the Board of Directors. As of December 31, 1999, the Company has not awarded any restricted stock or stock bonuses. F-18 In May 1997, the Company offered to its employees the opportunity to receive stock options to acquire shares of the Company's common stock at $5.00 to $5.50 per share in an exchange for a reduction in salary. Certain employees elected to reduce their salaries up to 100% for the period from May 1997 to October 1997 in exchange for 600 stock options for each $1,000 of salary reduction. As a result, the Company issued 267,079 stock options in exchange for salary reductions of $445,132. The Company recorded an expense relating to the issuance of these stock options in the amount of $74,189 per month for each of the six months from May 1997 to October 1997. During 1998, the Company awarded nonqualified stock options to outside consultants for services rendered. As a result, the Company recognized $62,000 in selling, general and administrative expense for the issue of these options. This amount represents the then fair market value of the services rendered to the Company based on the consultants' usual and customary charges for the services rendered. NOTE 10 - COMMITMENTS AND CONTINGENCIES The Company leases its office space under non cancelable operating leases expiring through May 2003. In June 1998, the Company consolidated its corporate offices into its San Antonio Research and Development facility. As a result of this move, the Company subleased its leased space in Newport Beach, CA. The sublease expires on the same date of the Company's lease in April 2001. The sublease income is aggregated with the net rent expense and included in other income and expense in the Consolidated Statements of Operations. The Company also leases certain office furniture and equipment under capitalized lease obligations. Future minimum rental commitments, net of sublease income, under lease agreements with initial or remaining terms of one year or more at December 31, 1999, are as follows: YEAR ENDING OPERATING CAPITAL DECEMBER 31 LEASES LEASES ----------- ----------- ---------- 2000 $ 80,132 $ 93,216 2001 76,151 63,961 2002 83,995 38,673 2003 35,003 11,174 ----------- ---------- $ 275,281 207,024 =========== Less- Amount representing interest 43,901 ---------- 163,123 Less- Current portion 63,877 ---------- Long-term portion $ 99,246 ========== Included in furniture and equipment is capitalized leased equipment of $377,627 with accumulated depreciation of $225,137 at December 31, 1999. Rent expense, net of sublease income, was $199,346, $220,587 and $102,815 for the years ended December 31, 1999, 1998 and 1997, respectively. F-19 EMPLOYMENT AGREEMENTS The Company entered into employment agreements with certain key employees of the Company which range from one to five years. SHEFFIELD UNIVERSITY MASTER AGREEMENT The Company has entered into an arrangement with Sheffield University (the Agreement) whereby the Company will undertake the development and commercialization of certain discoveries resulting from Sheffield University's research. The Agreement with Sheffield University (the University) is a five-year agreement with an automatic yearly renewal. In accordance with the Agreement, the Company issued 275,000 shares of common stock to the University for past research services, the value of which was expensed in the third quarter of 1999. Additionally, each year beginning July 1, 2000, the University will receive 25,000 stock options at the then current market price, plus 10,000 options for each new patent application filed in the previous 12 months. These options will be fully vested upon the grant date and have a five-year exercise period. The Company signed another agreement with the University for research and development services which automatically renews in one-year increments. Both agreements can be canceled if the key collaborator leaves the University. In September 1999, a five-year Consulting Agreement was entered into with the University's key collaborator. In accordance with the Consulting Agreement, the key collaborator received 200,000 shares of common stock for past research services, the value of which was expensed in the third quarter. The key collaborator will also receive 1% of the first $4 million of net sales under the PST Technology and 2% for sales above $4 million. Payments are required 45 days after each quarter end. Beginning July 1, 2000, in consideration for future services, the key collaborator will receive 25,000 stock options at the then current market price. These options have a five-year exercise period from the date of grant. NOTE 11 - SEGMENT INFORMATION During 1998, the Company adopted SFAS No. 131, "Disclosures about Segments of an Enterprise and Related Information." SFAS No. 131 establishes new standards for reporting information about operating segments in annual and interim financial statements, requiring that public business enterprises report financial and descriptive information about its reportable segments based on a management approach. SFAS No. 131 also establishes standards for related disclosures about products and services, geographic areas and major customers. In applying the requirements of this statement, each of the Company's geographic areas described below were determined to be an operating segment as defined by the statement, but have been aggregated as allowed by the statement for reporting purposes. As a result, the Company continues to have one reportable segment, which is the development of genetic susceptibility tests and therapeutic targets for common diseases. F-20 The following table presents information about the Company by geographic area: FOR THE YEARS ENDED DECEMBER 31 ----------------------------------------------- 1999 1998 1997 ----------- ----------- ----------- Total Revenues: United States ......... $ 281,239 $ 319,145 $ 171,358 France ................ 38,846 23,730 1,370 Other foreign ......... 157,412 70,067 23,200 ----------- ----------- ----------- Total ......... $ 477,497 $ 412,942 $ 195,928 =========== =========== =========== Operating Income: United States ......... $(3,650,968) $(7,576,319) $(3,552,646) France ................ (504,288) (563,337) (28,403) Other foreign ......... (2,043,484) (1,663,350) (480,990) ----------- ----------- ----------- Total ......... $(6,198,740) $(9,803,006) $(4,062,039) =========== =========== =========== AS OF DECEMBER 31 ------------------------------ 1999 1998 ---------- ---------- Assets: United States ....................... $3,176,159 $3,672,890 France .............................. -- -- Other foreign ....................... -- -- ---------- ---------- Total ................... $3,176,159 $3,672,890 ========== ========== CONCENTRATIONS OF RISK The Company sells products and provides contract services for customers primarily in the United States and France and extends credit based on an evaluation of the customer's financial condition, generally without requiring collateral. The Company monitors its exposure for credit losses and maintains allowances for anticipated losses. During the year ended December 31, 1999, no one customer accounted for more than 10% of total revenues. During the year ended December 31, 1999, the Company obtained lab services for its genetic susceptibility tests from two companies whose services comprised approximately 30% and 12% of cost of sales, respectively. NOTE 12 - SUBSEQUENT EVENTS In January 2000, the Company sold 832,667 shares of common stock in a private placement. The Company received net proceeds of approximately $4.7 million from this private placement. F-21 EX-10.25 2 EXHIBIT 10.25 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this "AGREEMENT), is made and entered into as of the 1st day of December, 1999 (the "EFFECTIVE DATE"), by and between INTERLEUKIN GENETICS, INC., a Texas corporation ("EMPLOYER"), and KENNETH S. KORNMAN, an individual ("EMPLOYEE"). R E C I T A L S A. Employer desires to obtain the benefit of the services of Employee and Employee desires to render such services to Employer. B. The Board of Directors of Employer (the "BOARD") has determined that it is in Employer's best interest to employ Employee and to provide certain benefits to Employee. C. Employer and Employee desire to set forth the terms and conditions of Employee's employment with Employer on the terms and subject to the conditions of this Agreement. A G R E E M E N T In consideration of the foregoing recitals and of the mutual covenants and conditions contained herein, the parties, intending to be legally bound, agree as follows: 1. TERM. Employer agrees to employ Employee, and Employee agrees to serve Employer, in accordance with the terms of this Agreement, for a term (the "TERM") beginning on the Effective Date and continuing for a period of three (3) years thereafter unless earlier terminated in accordance with the provisions hereof. 2. EMPLOYMENT OF EMPLOYEE. (a) SPECIFIC POSITIONS. Employer and Employee hereby agree that, subject to the provisions of this Agreement, Employer will employ Employee and Employee will serve as an employee of Employer. Employee shall have the title and perform the duties set forth on EXHIBIT A hereto and such other reasonable, usual and customary duties of such office as may be delegated to Employee from time to time by the Board, subject always to the policies as reasonably determined from time to time by the Board. (b) PROMOTION OF EMPLOYER'S BUSINESS. During the Term, Employee shall not engage in any business competitive with Employer. Employee agrees to devote his full business time, attention, knowledge, skill and energy to the business, affairs and interests of Employer and matters related thereto, and shall use his best efforts and abilities to promote Employer's 1 interests; PROVIDED, HOWEVER, that Employee is not precluded from devoting reasonable periods to time required: (i) for serving as a director or committee member of any organization that does not compete with Employer or that does not involve a conflict of interest with Employer; (ii) for managing his personal investments; so long as in either case, such activities do not materially interfere with the regular performance of his duties under this Agreement; or (iii) for delivering scientific lectures in the area of Periodontal Disease and Treatment and such other scientific areas as shall be approved by the President of Employer. 3. SALARY. Employer shall pay to Employee during the term of this Agreement a base salary ("BASE SALARY") of $200,000.00 per year, payable in equal monthly installments. The Base Salary may be increased (but not decreased) annually at the Employer's sole discretion throughout the Term on each anniversary of the Effective Date in the discretion of Employer's Board. In addition, at such time as a new President or Chief Executive Officer is recruited and hired by the Employer, Employee's salary shall automatically be adjusted to equal on a per month basis, at least eighty-five percent (85%) of the guaranteed, non-discretionary compensation being paid such new President or Chief Executive Officer. 4. BONUS. In addition to the Base Salary, Employee shall also receive a bonus, if any, as determined annually by the Board of Directors of Employer in its sole discretion. 5. BENEFITS. (a) FRINGE BENEFITS. During Employee's employment by Employer under this Agreement, Employee shall be eligible for participation in and shall be covered by any and all such medical, disability, life and other insurance plans and such other similar benefits available to other executive employees. Employer will pay life insurance premiums annually in the amount of $2720.00 on a policy for Employee; Employee shall have the right to designate ownership and beneficiary of said policy. Employee will receive a monthly automobile allowance of $600.00. (b) REIMBURSEMENTS. During Employee's employment with Employer under this Agreement, Employee shall be entitled to receive prompt reimbursement of all reasonable expenses incurred by Employee in performing services hereunder, including all expenses of travel at the request of, or in the service of, Employer provided that such expenses are incurred and accounted for in accordance with the policies and procedures established by Employer. (c) VACATION. During Employee's employment with Employer hereunder, Employee shall be entitled to an annual vacation leave of four (4) weeks at full pay, which shall be adjusted in accordance with the vacation policy generally applicable to employees of the Employer. 6. TERMINATION. (a) TERMINATION FOR CAUSE. Employer shall have the right, exercisable immediately upon written notice, to terminate Employee's employment for "Cause." 2 (i) DEFINITION OF CAUSE. As used herein, "CAUSE" means any of the following: (A) habitual drunkenness under the influence of alcohol by Employee or illegal use of narcotics; (B) Employee is convicted by a court of competent jurisdiction, or pleads "no contest" to, a felony or any other conduct of a criminal nature (other than minor traffic violations) by Employee; (C) Employee engages in fraud, embezzlement, or any other illegal conduct; (D) Employee imparts confidential information relating to Employer or its business to competitors or to other third parties other than in the course of carrying out Employee's duties; (E) Employee refuses to perform his duties hereunder or otherwise breaches any covenant, warranty or representation of this Agreement or Employee's Non-Disclosure and Confidentiality Agreement executed concurrently herewith, and, except for any conduct described in clauses (A) through (D) of this Section 6(a)(i), fails to cure such breach (if such breach is then capable of being cured) within ten (10) business days following written notice thereof specifying in reasonable detail the nature of such breach, or if such breach is not capable of being cured in such time, a cure shall not have been diligently initiated within such ten (10) business day period. (ii) EFFECT OF TERMINATION. Upon termination in accordance with this Section 6(a), Employee shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accrued hereunder through, but not including, the effective date of such termination. Employer's exercise of its right to terminate for Cause shall be without prejudice to any other remedy to which it may be entitled at law, in equity or under this Agreement. (b) VOLUNTARY TERMINATION. Employee may terminate his employment at any time by giving no less than thirty (30) days' written notice to Employer. (i) NO REASON. Upon termination in accordance with this Section 6(b), except as otherwise provided in Section 6(b)(ii), below, Employee shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accrued hereunder through, but not including, the effective date of such termination. (ii) GOOD REASON. Notwithstanding anything to the contrary in Section 6(b)(i) above, if Employee terminates his employment under this Section 6(b) for Good Reason (as defined below), Employee shall be entitled to receive from Employer all of the compensation and benefits provided for in Section 6(e) below. As used herein, "GOOD Reason" means any of the following: (A) the assignment to Employee of duties materially inconsistent with those of other employees of Employer in like positions where Employee provides written notice to Employer within six (6) months of such assignment that such duties are materially inconsistent with those duties of similarly situated employees and Employer fails to release Employee from his obligation to perform such inconsistent duties within twenty (20) business days after Employer's receipt of such notice; or (B) a failure by Employer to comply with any other material provision of Sections 3 through 5, inclusive, of this Agreement which has not been cured within fifteen (15) business days after notice of such noncompliance has been given by Employee to Employer, or if such failure is not capable of being cured in such time, a cure shall not have been diligently initiated by Employer within such fifteen (15) business day period. 3 (c) TERMINATION DUE TO DEATH OR DISABILITY. This Agreement shall automatically terminate upon the death of Employee. In addition, if Employee is unable to perform the essential functions of his job with or without a reasonable accommodation because of a physical or mental impairment for a period of six (6) months, Employer may terminate Employee's employment upon written notice to Employee. Upon termination in accordance with this Section 6(c), Employee (or Employee's estate, as the case may be) shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accrued hereunder through, but not including, the date of death or, in the case of disability, the date of termination. (d) TERMINATION UPON CESSATION OF BUSINESS. Employer shall have the right to immediately terminate Employee's employment under this Agreement upon a "Cessation of Business." For purposes of this Agreement, a "CESSATION OF BUSINESS" shall mean Employer's ceasing to operate in the ordinary course of business, whether by dissolution, liquidation, sale of assets, consolidation, merger or otherwise, in connection with, pursuant to or arising out of a good faith determination by the Board that the continuing operation of the business in its ordinary course is reasonably likely to render Employer unable to meet its liabilities as they mature. Upon termination in accordance with the Section 6(d), Employee shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accrued hereunder through, but not including, the effective date of such termination. If Employee is so terminated by Employer pursuant to this Section 6(d) during the Term, Employer shall (i) pay to Employee the Base Salary, and (ii) provide the same health insurance benefits to which Employee was entitled hereunder, in each case (i.e., the Base Salary and health insurance benefits), until the earlier to occur of (A) the expiration of the remaining portion of the Term, or (B) the expiration of the three (3) month period commencing on the date Employee is terminated. Employer may make such payments in accordance with its regular payroll schedule or in a single lump sum payment in its sole discretion. (e) TERMINATION WITHOUT CAUSE. Employer shall have the right, exercisable upon 30 days' prior written notice, to terminate Employee's employment under this Agreement for any reason other than set forth in Sections 6(a), (c) and (d) above, at any time during the Term. If Employee is so terminated by Employer pursuant to this Section 6(e) during the Term, Employer shall (i) pay to Employee the Base Salary, and (ii) provide the same health insurance benefits to which Employee was entitled hereunder, in each case (i.e., the Base Salary and health insurance benefits), until the earlier to occur of (A) the expiration of the remaining portion of the Term, or (B) the expiration of the twelve (12) month period commencing on the date Employee is terminated. Employer may make such payments in accordance with its regular payroll schedule or in a single lump sum payment in its sole discretion. 7. PUBLICITY. During the term of this Agreement and for a period of one (1) year thereafter, Employee shall not, directly or indirectly, originate or participate in the origination of any publicity, news release or other public announcements, written or oral, whether to the public 4 press or otherwise, relating to this Agreement, to any amendment hereto, to Employee's employment hereunder or to the Company, without the prior written approval of the Company. 8. RESTRICTIVE COVENANTS. (a) NON-COMPETITION. In consideration of the benefits of this Agreement, including Employee's access to and limited use of proprietary and confidential information of the Company, as well as training, education and experience provided to Employee by the Company directly and/or as a result of work projects assigned by the Company with respect thereto, Employee hereby covenants and agrees that during the term of this Agreement and for a period of twelve (12) months following termination of this Agreement, regardless of how such termination may be brought about, Employee shall not, directly or indirectly, as proprietor, partner, stockholder, director, officer, employee, consultant, joint venturer, investor or in any other capacity, engage in, or own, manage, operate or control, or participate in the ownership, management, operation or control, of any entity which engages anywhere in the world in any business activity which is competitive to current business activities in which the Company participates during Employee's employment with the Company; PROVIDED, HOWEVER, the foregoing shall not, in any event, prohibit Employee from purchasing and holding as an investment not more than 1% of any class of publicly traded securities of any entity which conducts a business in competition with the business of the Company, so long as Employee does not participate in any way in the management, operation or control of such entity. It is further recognized and agreed that, even though an activity may not be restricted under the foregoing provision, Employee shall not during the term of this Agreement and for a period of twelve (12) months following termination of this Agreement, regardless of how such termination may be brought about, provide any services to any person or entity which may be used against, or in conflict with the interests of, the Company or its customers or clients. (b) JUDICIAL REFORMATION. Employee acknowledges that, given the nature of the Company's business, the covenants contained in Section 8(a) establish reasonable limitations as to time, geographic area and scope of activity to be restrained and do not impose a greater restraint than is reasonably necessary to protect and preserve the goodwill of the Company's business and to protect its legitimate business interests. If, however, Section 8(a) is determined by any court of competent jurisdiction to be unenforceable by reason of its extending for too long a period of time or over too large a geographic area or by reason of it being too extensive in any other respect or for any other reason, it will be interpreted to extend only over the longest period of time for which it may be enforceable and/or over the largest geographic area as to which it may be enforceable and/or to the maximum extent in all other aspects as to which it may be enforceable, all as determined by such court. 5 (c) CUSTOMER LISTS; NON-SOLICITATION. In consideration of the benefits of this Agreement, including Employee's access to and limited use of proprietary and confidential information of the Company, as well as training, education and experience provided to Employee by the Company directly and/or as a result of work projects assigned by the Company with respect thereto, Employee hereby further covenants and agrees that for a period of twelve (12) months following the termination of this Agreement, regardless of how such termination may be brought about, Employee shall not, directly or indirectly, (i) use or make known to any person or entity the names or addresses of any clients or customers of the Company or any other information pertaining to them, (ii) call on for the purpose of competing, solicit, take away or attempt to call on, solicit or take away any clients or customers of the Company on whom Employee called or with whom he became acquainted during his employment with the Company, nor (iii) recruit or attempt to recruit any employees of the Company. (d) AFFILIATES. When used in this Section 8, the term "Company" includes Interluekin Genetics, Inc. and all affiliates and subsidiaries of Interluekin Genetics, Inc. 9. MISCELLANEOUS. (a) WITHHOLDINGS. All payments to Employee hereunder shall be made after reduction for all federal, state and local withholding and payroll taxes, all as determined under applicable law and regulations, and Employer shall make all reports and similar filings required by such law and regulations with respect to such payments, withholdings and taxes. (b) SUCCESSION. This Agreement shall inure to the benefit of and shall be binding upon Employer, its successors and assigns. The obligations and duties of Employee hereunder shall be personal and not assignable. (c) NOTICES. Any and all notices, demands, requests or other communications hereunder shall be in writing and shall be deemed duly given when personally delivered to or transmitted overnight express delivery or by facsimile to and received by the party to whom such notice is intended (provided the original thereof is sent by mail, in the manner set forth below, on the next business day after the facsimile transmission is sent), or in lieu of such personal delivery or overnight express delivery or facsimile transmission, on receipt when deposited in the United States mail, first-class, certified or registered, postage prepaid, return receipt requested, addressed to the applicable party at the address set forth below such party's signature to this Agreement. The parties may change their respective addresses for the purpose of this Section 9(c) by giving notice of such change to the other parties in the manner which is provided in this Section 9(c). (d) ENTIRE AGREEMENT. This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and it replaces and supersedes any prior agreements between the parties relating to said subject matter. 6 (e) HEADINGS. The headings of Sections herein are used for convenience only and shall not affect the meaning of contents hereof. (f) WAIVER; AMENDMENT. No provision hereof may be waived except by a written agreement signed by the waiving party. The waiver of any term or of any condition of this Agreement shall not be deemed to constitute the waiver of any other term or condition. This Agreement may be amended only by a written agreement signed by the parties hereto. (g) SEVERABILITY. If any of the provisions of this Agreement shall be held unenforceable by the final determination of a court of competent jurisdiction and all appeals therefrom shall have failed or the time for such appeals shall have expired, such provision or provisions shall be deemed eliminated from this Agreement but the remaining provisions shall nevertheless be given full effect. In the event this Agreement or any portion hereof is more restrictive than permitted by the law of the jurisdiction in which enforcement is sought, this Agreement or such portion shall be limited in that jurisdiction only to the extent required by the law of that jurisdiction. (h) GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas. (i) ARBITRATION. Except for the provisions of Sections 7 and 8 with regard to which the Company expressly reserves the right to petition a court directly for injunctive or other relief, any dispute arising out of or relating to this Agreement, or the breach, termination or the validity hereof, shall be settled by arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. Judgment upon the award rendered by the arbitrator or arbitrators may be entered in any court having jurisdiction thereof. THE ARBITRATOR OR ARBITRATORS ARE NOT EMPOWERED TO AWARD DAMAGES IN EXCESS OF COMPENSATORY DAMAGES (INCLUDING REASONABLE ATTORNEYS FEES AND EXPERT WITNESS FEES) AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO RECOVER SUCH DAMAGES (INCLUDING, WITHOUT LIMITATION, PUNITIVE DAMAGES) IN ANY FORUM. The arbitrator or arbitrators may award equitable relief in those circumstances where monetary damages would be inadequate. The arbitrator or arbitrators shall be required to follow the applicable law as set forth in the governing law section of this Agreement. The arbitrator or arbitrators shall award reasonable attorneys fees and costs of arbitration to the prevailing party in such arbitration. (j) EQUITABLE RELIEF. In the event of a breach or a threatened breach by Employee of any of the provisions contained in Sections 7 or 8 of this Agreement, Employee acknowledges that the Company will suffer irreparable injury not fully compensable by money damages and, therefore, will not have an adequate remedy available at law. Accordingly, the Company shall be entitled to obtain such injunctive relief or other equitable remedy from any court of competent jurisdiction as may be necessary or appropriate to prevent or curtail any such breach, threatened or actual, without having to post bond. The foregoing shall be in addition to 7 and without prejudice to any other rights that the Company may have under this Agreement, at law or in equity, including, without limitation, the right to sue for damages. IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above. "EMPLOYER": "EMPLOYEE": INTERLEUKIN GENETICS, INC. By: /s/ U. SPENCER ALLEN /s/ KENNETH S. KORNMAN U. SPENCER ALLEN KENNETH S. KORNMAN Address: Address: 100 NE Loop 410, Suite 820 3007 Orchard Hill San Antonio, TX 78216 San Antonio, TX 78216 8 EXHIBIT A DESCRIPTION OF JOB TITLE: Chief Scientific Officer DUTIES AND RESPONSIBILITIES: 1. Plan and oversee all research directed at discovering new technology to be commercialized by Interleukin Genetics, Inc. 2. Plan and oversee product development. 3. Develop a research and development plan and budget to be approved by the Board of Directors. 4. Have and supervise research and administrative staff as needed to perform above duties. 5. Participate in the planning and guidance of ILGN corporate strategy. 6. Manage the Research and Development budgets. 7. Other activities as designated by the CEO and Board of Directors. 8. Participate in business development activities. 9. Participate in activities related to protection of intellectual property. 9 EX-10.26 3 EXHIBIT 10.26 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this "AGREEMENT), is made and entered into as of the 1st day of April, 2000 (the "EFFECTIVE DATE"), by and between INTERLEUKIN GENETICS, INC., a Texas corporation ("EMPLOYER"), and PHILIP R. REILLY, an individual ("EMPLOYEE"). R E C I T A L S A. Employer desires to obtain the benefit of the services of Employee and Employee desires to render such services to Employer. B. The Board of Directors of Employer (the "BOARD") has determined that it is in Employer's best interest to employ Employee and to provide certain benefits to Employee. C. Employer and Employee desire to set forth the terms and conditions of Employee's employment with Employer on the terms and subject to the conditions of this Agreement A G R E E M E N T In consideration of the foregoing recitals and of the mutual covenants and conditions contained herein, the parties, intending to be legally bound, agree as follows: 1. TERM. Employer agrees to employ Employee, and Employee agrees to serve Employer, in accordance with the terms of this Agreement, for a term (the "TERM") beginning on the Effective Date and continuing for a period of three (3) years thereafter unless earlier terminated in accordance with the provisions hereof. 2. EMPLOYMENT OF EMPLOYEE. (a) SPECIFIC POSITIONS. Employer and Employee hereby agree that, subject to the provisions of this Agreement, Employer will employ Employee and Employee will serve as an employee of Employer. Employee shall have the title and perform the duties set forth on EXHIBIT A hereto and such other reasonable, usual and customary duties of such office as may be delegated to Employee from time to time by the Board, subject always to the policies as reasonably determined from time to time by the Board. The place of employment will be within a sixty mile radius of Boston, MA. (b) PROMOTION OF EMPLOYER'S BUSINESS. During the Term, Employee shall not engage in any business competitive with Employer. Employee agrees to devote his full business time, attention, knowledge, skill and energy to the business, affairs and interests of Employer and matters related thereto, and shall use his best efforts and abilities to promote Employer's interests; PROVIDED, HOWEVER, that Employee is not precluded from devoting reasonable periods to time required: (i) for serving as a director or committee member of any organization that does not compete with Employer or that does not involve a conflict of interest with Employer; (ii) for 1 managing his personal investments; so long as in either case, such activities do not materially interfere with the regular performance of his duties under this Agreement or (iii) for delivering lectures in the area of genetics and bioethics. Employer acknowledges that Employee will maintain a consulting relationship with Gene Sage Incorporated, based in San Francisco, California, with the understanding that this relationship will not conflict with Employee's duties with Employer. 3. SALARY. Employer shall pay to Employee during the term of this Agreement a base salary ("BASE SALARY") of $325,000.00 per year, payable in equal monthly installments. The Base Salary may be increased (but not decreased) annually at the Employer's sole discretion throughout the Term on each anniversary of the Effective Date in the discretion of Employer's Board of Directors. 4. BONUS. In addition to the Base Salary, Employee shall also receive a bonus, if any, as determined annually by the Board of Directors of Employer in its sole discretion. 5. STOCK OPTIONS. In addition, Employee shall receive an award of 500,000 stock options, of which 148,606 are incentive stock options and 351,394 are non-qualified stock options. This award was made effective December 1, 1999, the Employee's hire date under previous agreement, and is at a strike price of $2.875. This award will vest over 36 months in equal increments commencing December 1, 1999m unless Employee's employment is terminated prior to expiration of that 36 month period. These awards will be covered in detail by separate Option Agreements. 6. BENEFITS. (a) FRINGE BENEFITS. During Employee's employment by Employer under this Agreement, Employee shall be eligible for participation in and shall be covered by any and all such medical, disability, life and other insurance plans and such other similar benefits available to other executive employees. Employer will pay $2,720 to Employee each year on the annual anniversary date of this agreement, as reimbursement for life insurance premiums. Employee shall receive a monthly automobile allowance of $600.00. (b) REIMBURSEMENTS. During Employee's employment with Employer under this Agreement, Employee shall be entitled to receive prompt reimbursement of all reasonable expenses incurred by Employee in performing services hereunder, including all expenses of travel at the request of, or in the service of, Employer provided that such expenses are incurred and accounted for in accordance with the policies and procedures established by Employer. (c) VACATION. During Employee's employment with Employer hereunder, Employee shall be entitled to an annual vacation leave of four (4) weeks at full pay, which shall be adjusted in accordance with the vacation policy generally applicable to employees of the Employer and Holdings. 2 7. TERMINATION. (a) TERMINATION FOR CAUSE. Employer shall have the right, exercisable immediately upon written notice, to terminate Employee's employment for "Cause." (i) DEFINITION OF CAUSE. As used herein, "CAUSE" means any of the following: (A) habitual drunkenness under the influence of alcohol by Employee or illegal use of narcotics; (B) Employee is convicted by a court of competent jurisdiction, or pleads "no contest" to, a felony or any other conduct of a criminal nature (other than minor traffic violations) by Employee; (C) Employee engages in fraud, embezzlement, or any other illegal conduct; (D) Employee imparts confidential information relating to Employer or its business to competitors or to other third parties other than in the course of carrying out Employee's duties; (E) Employee refuses to perform his duties hereunder or otherwise breaches any covenant, warranty or representation of this Agreement or Employee's Non-Disclosure and Confidentiality Agreement executed concurrently herewith, and, except for any conduct described in clauses (A) through (D) of this Section 6(a)(i), fails to cure such breach (if such breach is then capable of being cured) within ten (10) business days following written notice thereof specifying in reasonable detail the nature of such breach, or if such breach is not capable of being cured in such time, a cure shall not have been diligently initiated within such ten (10) business day period. (ii) EFFECT OF TERMINATION. Upon termination in accordance with this Section 6(a), Employee shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accrued hereunder through, but not including, the effective date of such termination. Employer's exercise of its right to terminate for Cause shall be without prejudice to any other remedy to which it may be entitled at law, in equity or under this Agreement. (b) VOLUNTARY TERMINATION. Employee may terminate his employment at any time by giving no less than thirty (30) days' written notice to Employer. (i) NO REASON. Upon termination in accordance with this Section 6(b), except as otherwise provided in Section 6(b)(ii), below, Employee shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accured hereunder through, but not including, the effective date of such termination. (ii) GOOD REASON. Notwithstanding anything to the contrary in Section 6(b)(i), above, if Employee terminates his employment under this Section 6(b) for Good Reason (as defined below), Employee shall be entitled to receive from Employer all of the compensation and benefits provided for in Section 6(e), below. As used herein, "GOOD REASON" means any of the following: (A) the assignment to Employee of duties materially inconsistent with those of other employees of Employer in like positions where Employee provides written notice to Employer within six (6) months of such assignment that such duties are materially inconsistent with those duties of similarly situated employees and Employer fails to release Employee from his obligation to perform such inconsistent duties within twenty (20) business days after Employer's receipt of such notice; or (B) a failure by Employer to comply with any other material provision of Sections 3 through 5, inclusive, of this Agreement which has not been 3 cured within fifteen (15) business days after notice of such noncompliance has been given by Employee to Employer, or if such failure is not capable of being cured in such time, a cure shall not have been diligently initiated by Employer within such fifteen (15) business day period. (c) TERMINATION DUE TO DEATH OR DISABILITY. This Agreement shall automatically terminate upon the death of Employee. In addition, if Employee is unable to perform the essential functions of his job with or without a reasonable accommodation because of a physical or mental impairment for a period of six (6) months, Employer may terminate Employee's employment upon written notice to Employee. Upon termination in accordance with this Section 6(c), Employee (or Employee's estate, as the case may be) shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accrued hereunder through, but not including, the date of death or, in the case of disability, the date or termination. (d) TERMINATION UPON CESSATION OF BUSINESS. Employer shall have the right to immediately terminate Employee's employment under this Agreement upon a "Cessation of Business." For purposes of this Agreement, a "CESSATION OF BUSINESS" shall mean Employer's ceasing to operate in the ordinary course of business, whether by dissolution, liquidation, sale of assets, consolidation, merger or otherwise, in connection with, pursuant to or arising out of a good faith determination by the Board that the continuing operation of the business in its ordinary course is reasonably likely to render Employer unable to meet its liabilities as they mature. Upon termination in accordance with the Section 6(d), Employee shall be entitled to no further compensation hereunder other than the Base Salary and other benefits accrued hereunder through, but not including, the effective date of such termination. If Employee is so terminated by Employer pursuant to this Section 6(d) during the Term, Employer shall (i) pay to Employee the Base Salary, and (ii) provide the same health insurance benefits to which Employee was entitled hereunder, in each case (i.e., the Base Salary and health insurance benefits), until the earlier to occur of (A) the expiration of the remaining portion of the Term, or (B) the expiration of the three (3) month period commencing on the date Employee is terminated. Employer may make such payments in accordance with its regular payroll schedule or in a single lump sum payment in its sole discretion. (e) TERMINATION WITHOUT CAUSE. Employer shall have the right, exercisable upon 30 days' prior written notice, to terminate Employee's employment under this Agreement for any reason other than set forth in Sections 6(a), (c) and (d), above, at any time during the Term. If Employee is so terminated by Employer pursuant to this Section 6(e) during the Term, Employer shall (i) pay to Employee the Base Salary, and (ii) provide the same health insurance benefits to which Employee was entitled hereunder, in each case (i.e., the Base Salary and health insurance benefits), until the earlier to occur of (A) the expiration of the remaining portion of the Term, or (B) the expiration of the twelve (12) month period commencing on the date Employee is terminated. Employer may make such payments in accordance with its regular payroll schedule or in a single lump sum payment in its sole discretion. 8. MISCELLANEOUS. 4 (a) WITHHOLDINGS. All payments to Employee hereunder shall be made after reduction for all federal, state and local withholding and payroll taxes, all as determined under applicable law and regulations, and Employer shall make all reports and similar filings required by such law and regulations with respect to such payments, withholdings and taxes. (b) SUCCESSION. This Agreement shall inure to the benefit of and shall be binding upon Employer, its successors and assigns. The obligations and duties of Employee hereunder shall be personal and not assignable. (c) NOTICES. Any and all notices, demands, requests or other communications hereunder shall be in writing and shall be deemed duly given when personally delivered to or transmitted overnight express delivery or by facsimile to and received by the party to whom such notice is intended (provided the original thereof is sent by mail, in the manner set forth below, on the next business day after the facsimile transmission is sent), or in lieu of such personal delivery or overnight express delivery or facsimile transmission, on receipt when deposited in the United States mail, first-class, certified or registered, postage prepaid, return receipt requested, addressed to the applicable party at the address set forth below such party's signature to this Agreement. The parties may change their respective addresses for the purpose of this Section 8(c) by giving notice of such change to the other parties in the manner which is provided in this Section 8(c). (d) ENTIRE AGREEMENT. This Agreement contains the entire agreement of the parties relating to the subject matter hereof, and it replaces and supersedes any prior agreements between the parties relating to said subject matter. (e) HEADINGS. The headings of Sections herein are used for convenience only and shall not affect the meaning of contents hereof. (f) WAIVER; AMENDMENT. No provision hereof may be waived except by a written agreement signed by the waiving party. The waiver of any term or of any condition of this Agreement shall not be deemed to constitute the waiver of any other term or condition. This Agreement may be amended only by a written agreement signed by the parties hereto. (g) SEVERABILITY. If any of the provisions of this Agreement shall be held unenforceable by the final determination of a court of competent jurisdiction and all appeals therefrom shall have failed or the time for such appeals shall have expired, such provision or provisions shall be deemed eliminated from this Agreement but the remaining provisions shall nevertheless be given full effect. In the event this Agreement or any portion hereof is more restrictive than permitted by the law of the jurisdiction in which enforcement is sought, this Agreement or such portion shall be limited in that jurisdiction only to the extent required by the law of that jurisdiction. (h) GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of Texas. 5 (i) ARBITRATION. Any dispute arising out of or relating to this Agreement, or the breach, termination or the validity hereof, shall be settled by arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association. Judgment upon the award rendered by the arbitrator or arbitrators may be entered in any court having jurisdiction thereof. THE ARBITRATOR OR ARBITRATORS ARE NOT EMPOWERED TO AWARD DAMAGES IN EXCESS OF COMPENSATORY DAMAGES (INCLUDING REASONABLE ATTORNEYS FEES AND EXPERT WITNESS FEES) AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT TO RECOVER SUCH DAMAGES (INCLUDING, WITHOUT LIMITATION, PUNITIVE DAMAGES) IN ANY FORUM. The arbitrator or arbitrators may award equitable relief in those circumstances where monetary damages would be inadequate. The arbitrator or arbitrators shall be required to follow the applicable law as set forth in the governing law section of this Agreement. The arbitrator or arbitrators shall award reasonable attorneys fees and costs of arbitration to the prevailing party in such arbitration. IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first set forth above. "EMPLOYER": "EMPLOYEE": INTERLEUKIN GENETICS, INC. By:/s/ KENNETH S. KORNMAN /s/ PHILIP R. REILLY KENNETH S. KORNMAN PHILIP R. REILLY Address: Address: 100 N.E. Loop 410, Suite 820 145 Monument St. San Antonio, TX 78216 Concord, MA 01742 6 EXHIBIT A DESCRIPTION OF JOB TITLE: Chairman of the Board and Chief Executive Officer DUTIES AND RESPONSIBILITIES: 1. Plan and execute overall corporate strategy 2. Conduct Board of Directors meetings as required 3. Lead the Company's business development activities 4. Other activities as designated by the Board of Directors. 7 EX-10.27 4 EXHIBIT 10.27 SEVERANCE AGREEMENT This Severance Agreement is entered into this 20th day of September, 1999 by and between Paul J. White ("White") and Interleukin Genetics, Inc. ("ILGN"). W I T N E S S E T H: - - - - - - - - - - - WHEREAS, White is presently employed as the Senior Vice President and General Counsel of ILGN pursuant to the Employment Agreement dated January 1, 1996, as amended, between ILGN and White (the "Employment Agreement"). WHEREAS, the Company and White wish to discontinue their employment relationship and, in lieu thereof, enter into this Severance Agreement (the "Agreement"); NOW, THEREFORE, in consideration of the premises, the agreements herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and White agree as follows: 1. This Agreement embodies the full and final settlement of all rights and obligations of the Company and White under the Employment Agreement and the Employment Agreement shall be terminated in all respects except for the terms thereof that specifically survive as set forth in this Agreement. Each party hereto acknowledges that the Employment Agreement is being terminated without cause by mutual agreement of the parties hereto pursuant to Section 12.1.3 of the Employment Agreement. ILGN and White acknowledge and agree that White is not owed any amounts under the Employment Agreement resulting from this mutual agreement to terminate, and that no compensation or payment of monies how so ever characterized is due to White upon or subsequent to such termination of the Employment Agreement or termination of his employment. 2. White acknowledges that, effective August 31, 1999, White's employment with ILGN will be terminated. ILGN hereby acknowledges and agrees that White shall be entitled to retain the laptop computer, facsimile machine, and printer that White currently has in his possession. White also agrees that he will return his corporate American Express card on September 30, 1999, and ILGN will continue to pay for the telephone and fax lines to his home office until September 30, 1999. ILGN acknowledges that the desk, credenza and coat rack being utilized in one of the ILGN offices are the property of White, and White agrees that ILGN is entitled to use such property until White asks for its return or until ILGN wishes to return it to White, which ever occurs earlier. 3. In consideration for the release contained herein, ILGN agrees to pay White, by ILGN check on the eighth day following White's execution of this Agreement and provided White has not revoked this Agreement in the seven-day period following his execution of this Agreement, a lump sum payment equal to $104,673.99 (less standard legal deductions). White acknowledges that this lump sum payment includes total payment due him for accrued vacation under the Employment (1) white severance agr 9-21-99.doc Agreement. White releases the Company from all liabilities under, and all obligations to perform or observe any term or provision of, the Employment Agreement. 4. In further consideration for the release contained herein, ILGN agrees to pay each month for 18 months for the cost of White's COBRA health insurance for he and his immediate family, provided that White completes the paperwork for conversion of his current coverage to COBRA coverage within the prescribed statutory timeframe. This reimbursement is for coverage for the time period September 1, 1999 to February 28, 2001. White acknowledges that ILGN has provided him with the paperwork for COBRA conversion. 5. ILGN also agrees to fully vest White's ILGN stock options. ILGN also agrees to convert each of his four option grants from incentive stock options to non-qualified stock options under the 1996 Equity Incentive Plan. White acknowledges that ILGN has provided him with amendments to each of his four stock option grants which provide for full vesting and conversion to non-qualified stock options. The table below lists White's four stock option agreements, each of which have been amended to reflect full vesting and conversion to restricted stock options. --------------------------------------- # OF STRIKE DATE OF GRANT OPTIONS PRICE --------------------------------------- 1/1/97 10,000 $2.04 --------------------------------------- 5/1/97 15,000 $2.75 --------------------------------------- 12/1/98 5,312 $1.50 --------------------------------------- 3/18/99 14,166 $0.75 --------------------------------------- 6. ILGN shall pay White his full salary through August 31, 1999 and no other compensation or benefits shall be paid to White under the Employment Agreement or otherwise. Effective August 31, 1999, White shall not be entitled to any benefits (including medical and other insurance) from ILGN and shall not be a participant in ILGN's 401(k) Plan or the ILGN Profit Sharing Plan; provided, however, nothing herein shall effect White's eligibility to elect the continuation of health care coverage pursuant to Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"). 7. Each of White and the Company releases, remises, acquits and discharges the other party and their predecessors and affiliates, and their divisions, officers, directors, agents, employees, consultants, independent contractors, attorneys, advisers, successors and assigns, jointly and severally, from any and all claims, known or unknown, which releasing party, their heirs, successors or assigns have or may have against any of such parties and any and all liability that any of such parties may have to the released party whether denominated claims, demands, causes of action, obligations, damages or liabilities arising from any and all bases, however denominated, including but not limited to claims of discrimination under the Age Discrimination in Employment Act, as amended, Title VII of the Civil Rights Act of 1964, as amended, the Civil Rights Act of 1991, the Americans with Disabilities Act, the Employee Retirement Income Security Act of 1974, 42 U.S.C. ss. 1981, the Texas Commission on Human Rights Act, or any other U.S. federal, state or local law or any other law, rule or regulation or workers' compensation or disability claims under any such laws. This release relates to claims arising from and during White's relationship with ILGN and its predecessors and affiliates or as a result of the termination of such relationship. This release is for any relief, no matter how denominated, including but not limited to wages, back pay, front pay, (1) white severance agr 9-21-99.doc repayment of moving expense reimbursement, compensatory damages or punitive damages. Each party further agrees that they will not file or permit to be filed on their behalf any such claim. This release shall not apply to (i) the obligations set forth in this Agreement or those under the Confidentiality Agreement (as defined hereafter), (ii) ILGN's obligation to defend, indemnify and hold harmless White under its indemnification obligations to Officers and Directors under its Bylaws, or (iii) any other claims based on acts or omissions of any released party first occurring after the date on which he signs this Agreement. 8. For a period of one year, beginning September 1, 1999 and ending August 31, 2000, White agrees that he will not, directly or indirectly, work for, provide consulting services on his own behalf for, own an interest in (excluding a passive investment in a public company where White owns less than 5% of the stock of such company), operate, join, control, or participate in, or be connected as an officer, employee, agent, independent contractor, partner, shareholder, or principal of any corporation, partnership, proprietorship, firm, or association which conducts research and/or develops genetic diagnostics in clinical fields where ILGN currently is marketing or developing products, without the prior written consent of ILGN. This clause shall not restrict White from providing professional legal services to any Company. 9. This Agreement does not affect White's obligations or ILGN's rights under the Confidentiality and Invention Assignment Agreement ("Confidentiality Agreement") dated as of January 1, 1996, by and between ILGN and White; or any other confidentiality, secrecy or proprietary information or intellectual property agreement; or any laws governing such matters. 10. White acknowledges he received a copy of this Agreement on September 21, 1999. White shall have until and including October 12, 1999, to accept and consider this Agreement, a period White acknowledges to be twenty-one (21) days following receipt of this Agreement. 11. This Agreement shall not become effective and enforceable until seven (7) days following its execution. White may revoke this Agreement in a writing delivered to and received by U. Spencer Allen, CFO, Interleukin Genetics, Inc., 100 N.E. Loop 410, #820, San Antonio, Texas 78216, within said seven (7) days. 12. This Agreement is personal to White and, without the prior written consent of the Board of Directors of ILGN, shall not be assignable by White otherwise than by will or the laws of descent and distribution. The terms of this Agreement shall be binding and inure to the benefit of the parties hereto and their affiliates and their respective successors and assigns. The terms of this Agreement may be changed, modified or discharged only by an instrument in writing signed by the parties hereto. This Agreement shall be construed, enforced and interpreted in accordance with applicable federal law and the laws of the State of California without reference to its principles of conflicts of law. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be original. 13. The parties each agree that White is no longer an employee of ILGN. White shall take no unilateral action or incur any expense, and has no express or implied authority to do either, on behalf of ILGN, as an independent contractor, a consultant or otherwise, unless he has received written instructions from ILGN's President to so proceed. White further represents that he maintains a (1) white severance agr 9-21-99.doc separate place of business, serves customers other than ILGN, has all necessary permits and licenses to conduct the services under this Agreement, withholds and pays all state and federal income, social security, disability and insurance taxes and maintains adequate insurance. The parties further agree that nothing contained in this Agreement shall be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturers. 14. The failure of either party at any time to enforce any of the provisions of this Agreement or to require performance by the other party of any provision hereof shall not be construed to be a waiver of such provisions or to affect the validity of this Agreement, or of any part hereof, or of the right of either party thereafter to enforce each and every provision of this Agreement in accordance with its terms. 15. Written notices required or furnished under this Agreement shall be sent to the following addresses: to ILGN: U. Spencer Allen Interleukin Genetics, Inc. 100 N.E. Loop 410, #820 San Antonio, Texas 78216 to White: Paul J. White 134 East Hermosa San Antonio, TX 78212 16. Notices shall be effective on the first business day following receipt thereof. Notices sent by mail shall be deemed received on the date of delivery shown on the return receipt. 17. This Agreement represents and contains the entire agreement between the parties hereto with respect to the subject matter hereof, and the terms of this Agreement are contractual and not a mere recital. Further, this Agreement supersedes any and all prior oral and written agreements and understandings, and no representation, warranty, condition, understanding, or agreement of any kind with respect to the subject matter hereof shall be relied upon by the undersigned unless incorporated herein. 18. Except for the provisions of Paragraph 7 regarding the Confidentiality Agreement, with respect to which the Company expressly reserves the right to petition a court directly for injunctive and other relief, any claim, dispute or controversy of any nature whatsoever, including but not limited to tort claims or contract disputes, between the parties to this Agreement or their respective heirs, executors, administrators, legal representatives, successors and assigns, as applicable, arising out of or relating to the terms or conditions of this Agreement or the Employment Agreement hereby terminated, including the implementation, applicability and interpretation thereof, shall be resolved exclusively as follows: Upon the written request of one party served upon the other, any such claim, dispute or controversy shall be submitted to and settled by arbitration in accordance with the provisions of the Federal Arbitration Act, 9 U.S.C. ss.ss. 1-14, as amended. If arbitration is requested, each of the parties to this Agreement shall (1) white severance agr 9-21-99.doc appoint one person as an arbitrator to hear and determine any such disputes. The two arbitrators shall then choose a third arbitrator from a panel made up of experienced arbitrators selected pursuant to the procedures of the American Arbitration Association (the "AAA"). The majority decision of the three arbitrators shall be final, binding and conclusive upon the parties to this Agreement. Each party shall be responsible for the fees and expenses of its arbitrator and the fees and expenses of the third arbitrator shall be shared equally by the parties; PROVIDED, HOWEVER, to the extent possible, the arbitrators shall, as part of their decision, provide that the non-prevailing party shall pay all costs incurred by the prevailing party (including fees and costs of the arbitrators and the prevailing party's legal counsel). The terms of the commercial arbitration rules of AAA shall apply except to the extent they conflict with the provisions of this paragraph. Arbitration shall take place in San Antonio, Texas. It is further agreed that any of the parties hereto may petition the United States District Court for the State of Texas for a judgment to be entered upon any award entered through such arbitration proceedings. (a) The parties hereto acknowledge that their legal counsel has advised them, and that they are familiar with, the provision of Section 1542 of the California Civil Code, which provides as follows: "A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR." (b) Being aware of said Civil Code Section 1542, the parties hereto expressly waive and relinquish any rights or benefits they may have thereunder, as well as under any other state or federal statutes or common law principles of similar effect. IN WITNESS WHEREOF, ILGN has caused this Agreement to be executed by its duly authorized officer, and White has executed this Agreement, in each case as of the date first above written. Interleukin Genetics, INC. By: _______________ Name: U. Spencer Allen Title: C.F.O. (1) white severance agr 9-21-99.doc White acknowledges that he has read the foregoing Agreement and knows its contents and fully understands it. White acknowledges that he has been advised to consult with an attorney prior to executing this Agreement, has had such opportunity, and he is executing the Agreement voluntarily, fully understanding the significance and consequences of this Agreement. WHITE _____________ Paul J. White (1) white severance agr 9-21-99.doc EX-23.1 5 EXHIBIT 23.1 CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS As independent public accountants, we hereby consent to the incorporation of our reports, included in this Form 10-K, to the Company's previously filed Registration Statements on Form S-3/A (No. 333-83631) and Form S-8 (Nos. 333-47343, 333-67147 and 333-32538). /s/ ARTHUR ANDERSEN LLP San Antonio, Texas April 13, 2000 EX-23.2 6 EXHIBIT 23.2 CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS We hereby consent to the incorporation of our report, dated March 13, 1998, included in this Form 10-K in the previously filed Registration Statements of Interleukin Genetics, Inc. (formerly known as Medical Science Systems, Inc.) and subsidiary on Form S-3/A (File No. 333-83631, effective September 25, 1997) and on Form S-8 (File No. 333-47343, effective March 4, 1998, File No. 333-67147, effective November 12, 1998 and File No. 333-32538, effective March 15, 2000). SINGER LEWAK GREENBAUM & GOLDSTEIN LLP Los Angeles, California April 13, 2000 EX-27 7
5 1,000 YEAR DEC-31-1999 DEC-31-1999 2,656,116 0 158,301 55,300 0 2,891,678 813,592 529,111 3,176,159 923,735 0 0 0 23,177,865 (21,012,189) 3,176,159 477,497 477,497 201,182 6,475,056 0 0 59,189 (6,138,603) 0 0 0 0 0 (6,138,603) (1.15) (1.15)
-----END PRIVACY-ENHANCED MESSAGE-----